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A B S T R A C T
Background
Early accurate detection of all skin cancer types is important to guide appropriate management and improve morbidity and survival.
Basal cell carcinoma (BCC) is usually a localised skin cancer but with potential to infiltrate and damage surrounding tissue, whereas
cutaneous squamous cell carcinoma (cSCC) and melanoma are higher risk skin cancers with the potential to metastasise and ultimately
lead to death.When used in conjunction with clinical or dermoscopic suspicion of malignancy, or both, reflectance confocal microscopy
(RCM) may help to identify cancers eligible for non-surgical treatment without the need for a diagnostic biopsy, particularly in people
with suspected BCC. Any potential benefit must be balanced against the risk of any misdiagnoses.
Objectives
To determine the diagnostic accuracy of RCM for the detection of BCC, cSCC, or any skin cancer in adults with any suspicious
lesion and lesions that are difficult to diagnose (equivocal); and to compare its accuracy with that of usual practice (visual inspection
or dermoscopy, or both).
Search methods
We undertook a comprehensive search of the following databases from inception to August 2016: Cochrane Central Register of
Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing
Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials
Registry Platform. We studied reference lists and published systematic review articles.
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Selection criteria
Studies of any design that evaluated the accuracy of RCM alone, or RCM in comparison to visual inspection or dermoscopy, or both, in
adults with lesions suspicious for skin cancer compared with a reference standard of either histological confirmation or clinical follow-
up, or both.
Data collection and analysis
Two review authors independently extracted data using a standardised data extraction and quality assessment form (based on QUADAS-
2). We contacted authors of included studies where information related to the target condition or diagnostic threshold were missing.
We estimated summary sensitivities and specificities using the bivariate hierarchical model. For computation of likely numbers of true-
positive, false-positive, false-negative, and true-negative findings in the ’Summary of findings’ tables, we applied summary sensitivity and
specificity estimates to lower quartile, median and upper quartiles of the prevalence observed in the study groups. We also investigated
the impact of observer experience.
Main results
The review included 10 studies reporting on 11 study cohorts. All 11 cohorts reported data for the detection of BCC, including 2037
lesions (464 with BCC); and four cohorts reported data for the detection of cSCC, including 834 lesions (71 with cSCC). Only one
study also reported data for the detection of BCC or cSCC using dermoscopy, limiting comparisons between RCM and dermoscopy.
Studies were at high or unclear risk of bias across almost all methodological quality domains, and were of high or unclear concern
regarding applicability of the evidence. Selective participant recruitment, unclear blinding of the reference test, and exclusions due to
image quality or technical difficulties were observed. It was unclear whether studies were representative of populations eligible for testing
with RCM, and test interpretation was often undertaken using images, remotely from the participant and the interpreter blinded to
clinical information that would normally be available in practice.
Meta-analysis found RCM to be more sensitive but less specific for the detection of BCC in studies of participants with equivocal
lesions (sensitivity 94%, 95% confidence interval (CI) 79% to 98%; specificity 85%, 95% CI 72% to 92%; 3 studies) compared to
studies that included any suspicious lesion (sensitivity 76%, 95% CI 45% to 92%; specificity 95%, 95% CI 66% to 99%; 4 studies),
although CIs were wide. At the median prevalence of disease of 12.5% observed in studies including any suspicious lesion, applying
these results to a hypothetical population of 1000 lesions results in 30 BCCs missed with 44 false-positive results (lesions misdiagnosed
as BCCs). At the median prevalence of disease of 15% observed in studies of equivocal lesions, nine BCCs would be missed with 128
false-positive results in a population of 1000 lesions. Across both sets of studies, up to 15% of these false-positive lesions were observed
to be melanomas mistaken for BCCs. There was some suggestion of higher sensitivities in studies with more experienced observers.
Summary sensitivity and specificity could not be estimated for the detection of cSCC due to paucity of data.
Authors’ conclusions
There is insufficient evidence for the use of RCM for the diagnosis of BCC or cSCC in either population group. A possible role for
RCM in clinical practice is as a tool to avoid diagnostic biopsies in lesions with a relatively high clinical suspicion of BCC. The potential
for, and consequences of, misclassification of other skin cancers such as melanoma as BCCs requires further research. Importantly, data
are lacking that compare RCM to standard clinical practice (with or without dermoscopy).
P L A I N L A N G U A G E S U M M A R Y
What is the diagnostic accuracy of reflectance confocal microscopy for the detection of basal or squamous cell carcinoma of
the skin in adults?
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate reflectance confocal microscopy (RCM) is on its own or compared to
inspection of a skin lesion with the naked eye alone or using a hand-held microscope called dermoscopy for diagnosing two common
forms of keratinocyte skin cancer: basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) in adults. Review authors
in Cochrane included 10 studies to answer this question.
Why is improving the diagnosis of BCC or cSCC important?
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There are a number of different types of skin cancer. BCC and cSCC are usually localised skin cancers. Making the correct diagnosis
is important because mistaking one skin cancer for another can lead to the wrong treatment being used or lead to a delay in effective
treatment. Amissed diagnosis of BCC (known as a false-negative result) can result in themissed BCCgrowing and causing disfigurement.
A missed diagnosis of cSCC is more serious as it could spread to other parts of the body. Diagnosing a skin cancer when it is not actually
present (a false-positive result) may result in unnecessary biopsy or treatment and can cause discomfort and worry to patients.
What was studied in the review?
Microscopic techniques are used by skin cancer specialists to provide a more detailed, magnified examination of suspicious skin lesions
than can be achieved using the naked eye alone. Currently, dermoscopy is used by doctors as part of the examination of suspicious skin
lesions. RCM is a new microscopic technique to increase the magnification. It is a hand-held device or static unit using infrared light
that can visualise deeper layers of the skin when compared with dermoscopy. Both techniques are painless procedures, but RCM is
more expensive, time consuming, and requires additional specialised training. Dermoscopy can be used by general practitioners (GP)
whereas RCM is likely to only be used by hospital specialists for people who have been referred with a skin lesion that is suspected to
be a skin cancer. We wanted to see if RCM should be used instead of, or as well as, inspection of a skin lesion with the naked eye alone
or using dermoscopy to diagnose BCC or cSCC. The accuracy of the test was looked at when used on people with any suspicious skin
lesion and also in people with skin lesions that were tricky to diagnose.
What are the main results of the review?
We found 10 studies that included information on 11 groups of people with lesions suspicious for skin cancer. The main results were
based on seven of the 11 sets of data: four in any lesion suspicious for skin cancer and three in particularly difficult to diagnose skin
lesions.
For the comparison of RCM versus dermoscopy, we found four sets of data that included 912 suspicious skin lesions. The results
suggested that in a group of 1000 people with any suspicious lesion, of whom 125 (12.5%) really do have BCC:
- an estimated 139 people will have an RCM result indicating BCC is present;
- of these, 44 (32%) people will not have BCC (false-positive results) including one person with a melanoma mistaken for a BCC;
- of the 861 people with an RCM result indicating that BCC is not present, 30 (3%) will actually have BCC.
The review also included three sets of data on people that had 668 particularly difficult to diagnose skin lesions, one comparing RCM
to dermoscopy. The results suggested that if RCM was to be used by skin specialists in a group of 1000 people, of whom 150 (15%)
really do have BCC:
- an estimated 269 people will have an RCM result indicating BCC is present;
- of these, 128 (48%) people will not have a BCC (known as a false-positive result), including as many as 19 people with melanomas
mistaken for BCCs;
- of the 732 people with an RCM result indicating that BCC is not present, nine (1%) will actually have BCC.
There was not enough evidence to determine the accuracy of RCM for the detection of cSCC in either population group.
How reliable are the results of this review?
There was a lot of variation in the results of the studies in this review. Poor reporting of study conductmade assessment of the reliability of
studies difficult. It was unclear whether studies were representative of populations eligible for testing with RCM, and test interpretation
was often undertaken using images, remotely from the patient and the interpreter blinded to clinical information that would normally
be available in practice. Only one study compared the accuracy of dermoscopy and RCM. Most studies were conducted by specialist
research teams with high levels of training and experience with RCM, meaning that RCM may appear better than it would be when
used in everyday practice. Most studies reported diagnosis based on observers’ subjective views, which might not be the same for people
using the technique in everyday practice. In nine studies, the diagnosis of skin cancer was made by a skin biopsy or by following up
those people over time to make sure they remained negative for skin cancer*. This is likely to have been a reliable method for deciding
whether patients really had skin cancer. In one study, the absence of skin cancer was made by experts looking at the skin, a method that
may be less reliable for deciding whether patients really had skin cancer.
Who do the results of this review apply to?
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Five studies were carried out in Europe (61%), and the rest in Asia, Oceania, North America, or more than one continent. The average
ages of people who took part ranged from 41 to 65 years. The percentage of people with BCC in these studies ranged from 6% to 83%
(a middle value of 12% for any suspicious lesion and 15% for difficult to diagnose skin lesions). For studies of RCM used for cSCC,
the percentage of people with cSCC ranged between 4% and 13%. In many studies it was not clear what tests people taking part had
received before RCM.
What are the implications of this review?
There was not enough good evidence to support the use of RCM for the diagnosis of BCC or cSCC outside of research studies. There
was a lot of variation and uncertainty in results and in the ways studies were carried out, reducing the reliability of findings. Using
RCMmight avoid the need for a diagnostic biopsy in people who see a doctor with a high suspicion of a BCC lesion, but more research
is needed to confirm this. Such research should compare RCM to dermoscopy in well-described groups of people with suspicious skin
lesions and they must say whether other skin cancers end up being missed or being wrongly classified as BCC.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies, biopsy or clinical follow-up were the reference standards (means of establishing final diagnoses).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question: What is the diagnostic accuracy of reflectance confocal microscopy for the detection of keratinocyte skin cancers in adults?
Population: Adults with lesions suspicious for skin cancer, including:
• in part icipants with any suspicious lesion, where RCM might be used as an alternat ive to dermoscopy or to supplement visual inspect ion alone
• in part icipants with equivocal lesions in whom a clear management decision could not be made following visual inspect ion and dermoscopy,
where RCM might be used as an addit ion to visual inspect ion or dermoscopy, or both
Index test: RCM
Comparator test: Visual inspect ion or dermoscopy, or both
Target condition: • BCC
• cSCC
Reference standard: Histology with or without long-term follow-up
Action: If accurate, negat ive results of RCM will stop pat ients having unnecessary excision of skin lesions; posit ive results could inform the use of non-
surgical management opt ions
Quantity of evidence Target condition Number of studies Total lesions Total cases
- BCC 10 (11 cohorts) 2037 464
- cSCC 4 (4 cohorts) 834 71
Limitations
Risk of bias: High (4/ 11) or unclear (3/ 11) risk for part icipant select ion with exclusion on image quality and use of a case-control design. Low risk for index test
(11/ 11). High risk f rom inadequate reference standard (2/ 11) and unclear blinding of the reference standard to the RCM result (8/ 11). Dif ferent ial
verif icat ion in 3/ 11, t im ing of tests not mentioned in 7/ 11, and exclusions due to technical dif f icult ies in 4/ 11
Applicability of evi-
dence to question:
High (8/ 11) or unclear (3/ 11) concern for part icipants and sett ing with narrowly def ined populat ions (3/ 11) or mult iple lesions per pat ient (5/ 11)
. High concern for index test (7/ 11) with remote RCM interpretat ion (5/ 11) blinded to clinical information (3/ 11), lack of detail on the diagnost ic
threshold (2/ 11), and novice RCM users (2/ 11). The studies were dominated by 1 part icularly expert research group (8/ 11). Lit t le information given
concerning the expert ise of the histopathologist
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FINDINGS:
10 studies providing data for 11 cohorts of lesions were eligible for inclusion, 7 in our target populat ions of interest. All 7 cohorts reported data for detect ion of BCC and
2 reported data for detect ion of cSCC. The f indings presented were based on results f rom these 7 cohorts. Insuf f icient data were available to compare RCM with visual
inspect ion or dermoscopy or to consider the ef fect of using formally developed algorithms to assist RCM diagnosis. There was some evidence of melanomas or SCCs being
misdiagnosed as BCCs and of higher sensit ivity in cohorts using more experienced observers
Test: RCM for detection of BCC using any or no algorithm at any threshold in any suspicious lesion
Datasets (n) Lesions (n) Cases (n) Sensitivity (95% CI) Specificity (95% CI)
4 912 107 76% (45% to 92%) 95% (66% to 99%)
Numbers in a cohort of
1000 lesionsa
True positives False positives False negatives True negatives PPV NPV
At median prevalence
12.5%
95
(56; 115)
44
(298; 9)
30
(69; 10)
831
(578; 866)
68%
(16; 93)
97%
(89; 99)
At lower quart ile preva-
lence 10%
75
(45; 91)
45
(306; 9)
24
(54; 8)
856
(595; 892)
63%
(13; 91)
97%
(92; 99)
At upper quart ile preva-
lence 15%
118
(70; 143)
42
(287; 8)
37
(85; 12)
803
(558; 837)
74%
(20; 94)
96%
(87; 99)
Test: RCM for detection of BCC using any or no algorithm at any threshold in equivocal lesions
Datasets (n) Lesions (n) Cases (n) Sensitivity (95% CI) Specificity (95% CI)
3 668 148 94% (79% to 98%) 85% (72% to 92%)
Numbers in a cohort of
1000 lesionsa
True
positives
False
positives
False
negatives
True
negatives
PPV NPV
At median prevalence
15%
141
(119; 147)
128
(238; 68)
9
(32; 3)
723
(612; 782)
53%
(33; 68)
99%
(95; 100)
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At lower quart ile preva-
lence 11%
100
(84; 104)
134
(250; 72)
6
(22; 2)
760
(644; 822)
43%
(25; 59)
99%
(97; 100)
At upper quart ile preva-
lence 29%
276
(232; 288)
106
(198; 56)
18
(62; 6)
600
(508; 650)
72%
(54; 84)
97%
(89; 99)
Test: RCM for detection of cSCC using any or no algorithm
- Lesions (n) Cases (n) Sensitivity (95% CI) Specificity (95% CI)
In any suspicious lesion
(1 study)
323 42 74% (58% to 86%) 92% (88% to 95%)
In equivocal lesions (1
study)
260 13 77% (46% to 95%) 98% (96% to 100%)
aNumber of true posit ives, false posit ives, false negat ives, and true negat ives have been est imated at the median and
interquart ile ranges of prevalence, at mean sensit ivity and specif icity and using the lower and upper lim its of the 95%
conf idence intervals, denoted in brackets (lower lim it ; upper lim it)
BCC: basal cell carcinoma; CI: conf idence interval; cSCC: cutaneous squamous cell carcinoma; n: number; NPV: negat ive
predict ive value; PPV: posit ive predict ive value; RCM: ref lectance confocal m icroscopy; SCC: squamous cell carcinoma.
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Accu-
racy (DTA) Reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers as part of the National Institute
for Health Research (NIHR) Cochrane Systematic Reviews Pro-
gramme. Appendix 1 shows the content and structure of the pro-
gramme.
Target condition being diagnosed
The most commonest skin cancers in white populations are those
arising from keratinocyte cells: basal cell carcinoma (BCC) and cu-
taneous squamous cell carcinoma (cSCC) (Gordon 2013; Madan
2010). BCC is the more common of the two keratinocyte carcino-
mas, and approximately around one third of people with a BCC
will develop a second BCC (Flohil 2013). In 2003, the World
Health Organization estimated that between two and three mil-
lion ’non-melanoma’ skin cancers (of which BCC and cSCC are
estimated to account for around 80% and 16% of cases respec-
tively) and 132,000 melanoma skin cancers occur globally each
year (WHO 2003).
In this diagnostic test accuracy (DTA) review, we collectively re-
ferred to BCC and cSCC using the new preferred and more accu-
rate term of ’keratinocyte carcinoma’ (Karimkhani 2015). Rather
than defining BCC and cSCC by what they are not (i.e. non-
melanoma skin cancer), we collectively refer to these conditions
using the preferred and more accurate term of ’keratinocyte carci-
noma’ in this DTA review (Karimkhani 2015).We define (a) BCC
and (b) cSCC as the primary target conditions for this review.
We also examine accuracy for the target condition of (c) any skin
cancer, including keratinocyte skin cancer, melanoma or atypical
intraepidermal melanocytic variants and any other skin cancer.We
have examined the accuracy of reflectance confocal microscopy
(RCM) for the diagnosis of melanoma in another review (Dinnes
2018a), which is one of a series of systematic reviews of diagnostic
tests for the diagnosis of keratinocyte skin cancers (Dinnes 2015a).
A table of acronyms used is provided in Appendix 2.
Basal cell carcinoma
BCCcan arise frommultiple stem cell populations, including from
the follicular bulge and interfollicular epidermis (Grachtchouk
2011). Growth is usually localised, but it can infiltrate and dam-
age surrounding tissue, which if left untreated can cause consider-
able destruction and disfigurement, particularly when located on
the face (Figure 1). The four main types of BCC are superficial,
nodular, morphoeic (infiltrative), and pigmented. Lesions typi-
cally present as slow-growing asymptomatic papules, plaques, or
noduleswhichmay bleed or formulcers that donot heal (Firnhaber
2012). People with a BCC often present themselves to health-
care professionals with a non-healing lesion rather than specific
symptoms such as pain. Many lesions are diagnosed incidentally
(Gordon 2013).
Figure 1. Sample photographs of superficial spreading melanoma (left), basal cell carcinoma (centre) and
cutaneous squamous cell carcinoma (right). Copyright © 2012 Dr Rubeta Matin: reproduced with permission.
BCC most commonly occurs on sun-exposed areas of the head
and neck (McCormack 1997), and are more common in men and
in people over the age of 40. A rising incidence of BCC in younger
people has been attributed to increased recreational sun exposure
(Bath-Hextall 2007a; Gordon 2013;Musah 2013). Other risk fac-
tors include Fitzpatrick skin types I and II (Fitzpatrick 1975; Lear
1997; Maia 1995); previous skin cancer history; immunosuppres-
sion; arsenic exposure; and genetic predisposition, such as in basal
cell naevus (Gorlin’s) syndrome (Gorlin 2004; Zak-Prelich 2004).
Annual incidence is increasing worldwide; Europe has experienced
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a mean increase of 5.5% per year since the 1970s, the USA 2%
per year, while estimates for the UK show incidence appears to be
increasing more steeply at a rate of an additional 6 per 100,000
persons per year (Lomas 2012). The rising incidence has been
attributed to an ageing population; changes in the distribution
of known risk factors, particularly ultraviolet radiation; and im-
proved detection due to the increased awareness among both prac-
titioners and the general population (Verkouteren 2017). Hoorens
2016 points to evidence for a gradual increase in the size of BCCs
over time, with delays in diagnosis ranging from 19 to 25 months.
According to National Institute for Health and Care Excellence
(NICE) guidance (NICE 2010), low risk BCCs are nodular le-
sions occurring in people older than 24 years who are not im-
munosuppressed and do not have Gorlin’s syndrome. Further-
more, lesions should be located below the clavicle; should be small
(less than 1 cm) with clinically well-defined margins; not recur-
rent following incomplete excision or other treatment; and not
in awkward or highly visible locations (NICE 2010). Superficial
BCCs are also typically low risk and may be amenable to medical
treatments such as cryotherapy, photodynamic therapy (PDT) or
topical immunomodulatory therapy, e.g. 5% Imiquimod cream
(Kelleners-Smeets 2017). Assigning BCCs as low or high risk in-
fluences the management options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can be found on the H-area
of the face (Lear 2014), can arise from long-standing untreated
lesions or from a recurrence of aggressive BCC after primary treat-
ment (Lear 2012). Very rarely, BCC may metastasize to regional
and distant sites resulting in death; this is particularly true for large
neglected lesions in people who are immunosuppressed, or those
with Gorlin syndrome (McCusker 2014). Rates of metastasis are
reported at 0.0028% to 0.55% (Lo 1991), with very poor survival
rates. It is recognised that basosquamous carcinoma (more like a
high-risk SCC in behaviour and not considered a true BCC) is
likely to have accounted for many cases of apparent metastases of
BCC, hence, the spuriously high reported incidence in some stud-
ies of up to 0.55%, which is not seen in clinical practice (Garcia
2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinising cells of the epidermis
or its appendages. People with cSCC often present with an ulcer
or firm (indurated) papule, plaque, or nodule (Griffin 2016), of-
ten with an adherent crust (Madan 2010) (Figure 1). cSCC can
arise in the absence of a precursor lesion or may develop from pre-
existing lesions, such as actinic keratosis or Bowen’s disease (con-
sidered by some clinicians to be cSCC in situ) with an estimated
annual risk of progression of less than 1% to 20% for newly-
arising lesions (Alam 2001) and 5% for pre-existing lesions (Kao
1986). It remains locally invasive for a variable length of time,
but has the potential to spread to the regional lymph nodes or via
the bloodstream to distant sites, especially in immunosuppressed
individuals (Lansbury 2010). High risk lesions are those arising
on the lip or ear; recurrent cSCC; lesions arising on non-exposed
sites; within scars, or chronic ulcers; tumours more than 20 mm in
diameter and depth of invasion more than 4 mm; and poor differ-
entiation on pathological examination (Motley 2009). Perineural
nerve invasion (PNI) of at least 0.1 mm in diameter is a further
documented risk factor for high-risk cSCC (Carter 2013).
Chronic ultraviolet light exposure through recreation or occupa-
tion is strongly linked to cSCC occurrence (Alam 2001). It is
particularly common in people with fair skin and in less com-
mon genetic disorders of pigmentation, such as albinism, xero-
derma pigmentosum, and recessive dystrophic epidermolysis bul-
losa (RDEB) (Alam 2001). Other recognised risk factors include
immunosuppression; chronic wounds; arsenic or radiation expo-
sure; certain drug treatments, such as voriconazole and BRAFmu-
tation inhibitors; and previous skin cancer history (Baldursson
1993; Chowdri 1996; Dabski 1986; Fasching 1989; Lister 1997;
Maloney 1996; O’Gorman 2014). In solid organ transplant re-
cipients, cSCC is the most common form of skin cancer; the risk
of developing cSCC has been estimated at 65 to 253 times that of
the general population (Hartevelt 1990; Jensen 1999; Lansbury
2010). Overall, local and metastatic recurrence of cSCC at five
years is estimated at 8% and 5% respectively. The five-year sur-
vival rate of metastatic cSCC of the head and neck is around 60%
(Moeckelmann 2018).
Treatment
Treatment options for BCC and cSCC include surgery, other de-
structive techniques, and topical chemotherapy. One Cochrane
Review of 27 randomised controlled trials (RCTs) of interventions
for BCC found very little good-quality evidence for any of the
interventions used (Bath-Hextall 2007b). Complete surgical ex-
cision of primary BCC has a reported five-year recurrence rate of
less than 2% (Griffiths 2005 (data 1998 to 2003); Walker 2006
(review paper)), leading to significantly fewer recurrences than
treatmentwith radiotherapy (Bath-Hextall 2007b). After apparent
clear histopathological margins (serial vertical sections) after stan-
dard excision biopsy with 4mm surgical peripheral margins taken,
there is a five-year reported recurrence rate of around 4% (Drucker
2017).Mohsmicrographic surgery, whereby horizontal sections of
the tumour are microscopically examined perioperatively and re-
excision is undertaken until the margins are tumour-free, can be
considered for high risk lesions on the face where standard wider
excisionmarginsmight lead to considerable functional or cosmetic
impairment (Bath-Hextall 2007b; Motley 2009; Lansbury 2010;
Stratigos 2015). Bath-Hextall 2007b found a single trial compar-
ing Mohs micrographic surgery with a 3 mm surgical margin ex-
cision in BCC (Smeets 2004); the update of this study showed
non-significantly lower recurrence at 10 years with Mohs micro-
graphic surgery (4.4% compared to 12.2% after surgical excision;
P = 0.10) (van Loo 2014).
The main treatments for high risk BCC are wide local excision,
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Mohs micrographic surgery and radiotherapy. For low risk or su-
perficial subtypes of BCC, or for small or multiple BCCs, or both,
at low risk sites (Marsden 2010), destructive techniques other than
excisional surgery may be used (e.g. electrodessication and curet-
tage or cryotherapy (Alam 2001; Bath-Hextall 2007b)). Alterna-
tively non-surgical (or non-destructive) treatments may be con-
sidered (Bath-Hextall 2007b; Drew 2017; Kim 2014), including
topical chemotherapy such as imiquimod (Williams 2017), 5-flu-
orouracil (5-FU) (Arits 2013), ingenol mebutate (Nart 2015) and
PDT (Roozeboom 2016). Non-surgical treatments are most fre-
quently used for superficial forms of BCC, with one head to head
trial suggesting topical imiquimod is superior to PDT and 5-FU
(Jansen 2018). Although non-surgical techniques are increasingly
used, they do not allow histological confirmation of tumour clear-
ance, and their use is dependent on accurate characterisation of the
histological subtype and depth of tumour. The 2007 systematic
review of BCC interventions found limited evidence from very
small RCTs for these approaches (Bath-Hextall 2007b), which
have only partially been filled by subsequent studies (Bath-Hextall
2014; Kim 2014; Roozeboom 2012). Most BCC trials have com-
pared interventions within the same treatment class, and few have
compared medical versus surgical treatments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway in-
hibitor, is now available for the treatment of metastatic or lo-
cally advanced BCC based on the pivotal study ERIVANCE BCC
(Sekulic 2012). It is licensed for use in people with BCC where
surgery or radiotherapy is inappropriate, e.g. for treating locally ad-
vanced periocular and orbital BCCs with orbital salvage of people
who otherwise would have required exenteration (Wong 2017).
However, in 2017, NICE recommended against the use of vis-
modegib based on cost-effectiveness and uncertainty of evidence
(NICE 2017).
A systematic review of interventions for primary cSCC found only
one RCT eligible for inclusion (Lansbury 2010). Current practice
therefore relies on evidence fromobservational studies, as reviewed
in Lansbury 2013, for example. Surgical excision with predeter-
mined margins is usually the first-line treatment (Motley 2009;
Stratigos 2015). Estimates of recurrence after Mohs micrographic
surgery, surgical excision, or radiotherapy, which are likely to have
been evaluated in higher risk populations, have shown pooled re-
currence rates of 3% (Mohs), 5.4% (surgical excision), and 6.4%
(radiotherapy) with overlapping confidence intervals (CI); the re-
view authors advise caution when comparing results across treat-
ments (Lansbury 2013).
Index test(s)
RCM, also known as confocal laser scanning microscopy or con-
focal microscopy, was first developed for skin imaging in the early
1990s (Rajadhyaksha 1995), and is emerging as a potential alter-
native or adjunct to dermoscopy for the diagnosis of skin cancer. It
is a non-invasive technology, which can be used to visualise hori-
zontally sectioned images of the skin at a cellular lateral resolution
of about 1 µm, in vivo to the depth of the upper dermis. The
contrast for the monochrome images produced is achieved by the
variation of the optical properties within the skin when illumi-
nated by a near-infrared light (830 nm) (see Figure 2). The greatest
contrast is achieved from melanin, so that RCM is advocated as
being particularly useful for assessing pigmented lesions.
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Figure 2. RCM images of normal skin (top) and of lentigo maligna (bottom). Copyright © 2017 Dr Rakesh
Patalay: reproduced with permission.
The Caliber ID VivaScope imaging systems are the only commer-
cially available RCM devices (distributed by MAVIG in Europe;
www.vivascope.de/en/home.html). The Vivascope 1500 (and the
previously available 1000 version) is a console-based unit with a
dermoscopic attachment, whereas the Vivascope 3000 is a hand-
held device designed for superior ergonomics, allowing imaging of
lesions inaccessible for the 1500 version (Figure 3). Imaging can
be undertaken by clinicians or technicians following appropriate
training (Edwards 2016). The length of time required for diagno-
sis has been estimated at 15 minutes for the Vivascope 1500 (10
minutes of a technician’s time for imaging and five minutes of a
dermatologist’s time for image interpretation) and 10 minutes for
the Vivascope 3000 (Edwards 2016). The company has estimated
the mean cost per use of the 1500 system, including dermoscopy,
as GBP 120 based on 2014 National Health Service (NHS) ref-
erence costs and an indicative price for Vivascope 1500 of GBP
95,224 (Edwards 2016).
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Figure 3. Caliber ID Vivascope 1500 with 3000 attachment. Copyright © 2017 Guy’s & St Thomas’ NHS
Foundation Trust: reproduced with permission.
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Various algorithms have been proposed for the interpretation of
RCM images, particularly for the diagnosis of melanoma (Dinnes
2018a); however, evaluation of lesion characteristics associated
with other types of skin cancer, especially BCC, is ongoing
(Gonzalez 2002; Guitera 2012). The lesion characteristics most
recently proposed to be associated with BCC include the pres-
ence of ’dark silhouettes’ or ’bright tumour islands’ plus at least
one of: ’streaming’ polarisation of nuclei in neoplastic aggregates
along the same axis of orientation; ’peripheral palisading’ of nuclei
at the tumour islands’ periphery; dark ’peritumoral clefts’ around
the tumour islands; fibrotic stroma with ’thickened collagen bun-
dles;’ dilated and tortuous ’linear blood vessels’ and ’coiled blood
vessels’; ’bright dendritic structures’ within tumour islands; and
’bright round cells’ in the stroma. Nevertheless, BCC and cSCC
specific criteria have yet to be fully established, with some sug-
gestion that the keratotic surface of SCC may prohibit the use of
imaging techniques (Edwards 2016).
Clinical pathway
The diagnosis of skin lesions occurs in primary, secondary, and
tertiary care settings by both generalist and specialist healthcare
providers. In the UK, people with concerns about a new or chang-
ing lesion will present to their GP rather than directly to a special-
ist in secondary care. If the GP has concerns then he/she usually
refers the person to a specialist in secondary care - usually a der-
matologist but sometimes to a surgical specialist such as a plastic
surgeon or an ophthalmic surgeon. Suspicious skin lesions may
also be identified in a referral setting, for example, by a general
surgeon, and referred for a consultation with a skin cancer special-
ist (Figure 4). Skin cancers identified by other specialist surgeons
(such as an ear, nose, and throat (ENT) specialist or maxillofacial
surgeon) will usually be diagnosed and treated without further re-
ferral.
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Figure 4. Current clinical pathway for people with skin lesions.
14Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Current UK guidelines recommend that all suspicious pigmented
lesions presenting in primary care should be assessed by taking a
clinical history and visual inspection using the seven-point check-
list (MacKie 1990); lesions suspected to be melanoma or cSCC
(London Cancer Alliance 2013) should be referred for appropri-
ate specialist assessment within two weeks (Chao 2013; Marsden
2010; NICE 2015). However, evidence is emerging to suggest that
excision of melanoma by GPs is not associated with increased risk
compared with outcomes in secondary care (Murchie 2017). In
the UK, low risk BCC are usually recommended for routine re-
ferral, with urgent referral for those in whom a delay could have a
significant impact on outcomes, for example, due to large lesion
size or critical site (NICE 2015). Appropriately qualified general-
ist care providers increasingly undertake management of low risk
BCC in the UK (NICE 2010) and Australia (CCAAC Network
2008).
For referred lesions, the specialist clinician will use history-taking,
visual inspection of the lesion (in conjunction with other skin le-
sions), and palpation of the lesion and associated lymph nodes in
conjunction with dermoscopic examination to inform a clinical
decision. If melanoma is suspected, then urgent 2 mm excision
biopsy is recommended (Lederman 1985; Lees 1991); for cSCC,
predetermined surgical margin excision or a diagnostic biopsy may
be considered. BCC and premalignant lesions potentially eligible
for non-surgical treatment may undergo a diagnostic biopsy be-
fore initiation of therapy if there is diagnostic uncertainty. Equiv-
ocal (or more difficult to diagnose) melanocytic lesions for which
a definitive clinical diagnosis cannot be reached may undergo
surveillance to identify any lesion changes that would indicate ex-
cision biopsy or reassurance and discharge for those that remain
stable over a period of time.
Theoretically, teledermatology consultations may aid appropriate
triage of lesions into urgent referral; non-urgent secondary care
referral (e.g. for suspected BCC); or where available, referral to
an intermediate care setting (e.g. clinics run by GPs with a spe-
cial interest in dermatology). The distinction between setting and
examiner qualifications and experience is important as specialist
clinicians might work in primary care settings (e.g. in the UK,GPs
with a special interest in dermatology and skin surgery who have
undergone appropriate training), and generalists might practice in
secondary care settings (e.g. plastic surgeons who do not specialise
in skin cancer). The level of skill and experience in skin cancer
diagnosis will vary for both generalist and specialist care providers
and will also impact on test accuracy.
Prior test(s)
The diagnosis of skin cancer is based on history-taking and clinical
examination. In the UK, this is typically undertaken at two deci-
sion points - first in the GP surgery where a decision is made to
refer or not to refer, and then a second time by a dermatologist or
other secondary care clinician where a decision is made to biopsy
or excise or not. Visual inspection of the skin is undertaken itera-
tively, using both implicit pattern recognition (non-analytical rea-
soning) and more explicit ’rules’ based on conscious analytical rea-
soning (Norman 2009), the balance of which will vary according
to experience and familiarity with the diagnostic question. Various
attempts have been made to formalise the ’mental rules’ involved
in analytical pattern recognition for melanoma (Friedman 1985;
Grob 1998; MacKie 1985; MacKie 1990; Sober 1979; Thomas
1998); however, visual inspection for keratinocyte skin cancers re-
lies primarily on pattern recognition. Accuracy varies according to
the expertise of the clinician. Primary care physicians have been
found to miss over half of BCC (Offidani 2002) and to inappro-
priately diagnose one third of BCC (Gerbert 2000). In contrast,
one Australian study found that trained dermatologists were able
to detect 98% of BCC, but with a specificity of only 45% (Green
1988).
A range of technologies have emerged to aid diagnosis to reduce
the number of diagnostic biopsies or inappropriate surgical proce-
dures. Dermoscopy using a hand-held microscope has become the
most widely used tool for clinicians to improve diagnostic accu-
racy of pigmented lesions, in particular for melanoma (Argenziano
1998; Argenziano 2012; Haenssle 2010; Kittler 2002), although
is less well established for the diagnosis of BCC or cSCC. The di-
agnostic accuracy, and comparative accuracy, of visual inspection
and dermoscopy for keratinocyte skin cancer has been evaluated
in a further review in this series (Dinnes 2018b).
Role of index test(s)
RCM is most likely to have a role as an additional test to better
identify lesions that can bemonitored or reassured as being benign,
instead of being sent for urgent excision (Edwards 2016), or for
low risk BCC to identify those eligible for non-surgical treatment
without the need for a diagnostic biopsy. RCM could also be con-
sidered as a primary diagnostic test (i.e. as a potential replacement
for dermoscopy).
Delay in diagnosis of a BCC as a result of a false-negative test
is not as serious as for melanoma because BCCs are usually slow
growing and very unlikely to metastasise (Betti 2017). However,
delayed diagnosis can result in a larger and more complex excision
with consequent greater morbidity. Very sensitive diagnostic tests
for BCC, however, may compromise on lower specificity leading
to a higher false-positive rate, and an enormous burden of skin
surgery, such that a balance between sensitivity and specificity is
needed. The situation for cSCC is more similar to melanoma in
that the consequences of falsely reassuring a person that they do
not have skin cancer can be serious and potentially fatal. Thus, a
good diagnostic test for cSCC should demonstrate high sensitivity
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and a corresponding high negative predictive value. A test that can
reduce false-positive clinical diagnoses without missing true cases
of disease has patient and resource benefits. False-positive clinical
diagnoses not only cause unnecessary morbidity from the biopsy,
but could lead to initiation of inappropriate therapies and also
increase patient anxiety.
A further postulated advantage of RCM is its ability to non-in-
vasively differentiate seborrhoeic keratoses or non-melanocytic le-
sions from a population of pigmented lesions (de Carvalho 2015;
Nascimento 2014; Menge 2016). RCM could also develop a role
in guiding definitive therapeutic margins (Edwards 2016), both
pre- and intraoperatively and to estimate response to topical che-
motherapy for lentigo maligna and potentially BCCs; however,
these uses are not under consideration in this review.
Alternative test(s)
A number of other tests have been reviewed as part of our se-
ries of Cochrane DTA reviews on the diagnosis of keratinocyte
skin cancers, including visual inspection and dermoscopy (Dinnes
2018b), teledermatology (Chuchu 2018a), mobile phone applica-
tions (Chuchu 2018b), computer-assisted diagnosis (CAD) tech-
niques (Ferrante di Ruffano 2018a), optical coherence tomog-
raphy (OCT) (Ferrante di Ruffano 2018b), exfoliative cytol-
ogy (Ferrante di Ruffano 2018c), and high-frequency ultrasound
(Dinnes 2018c).
OCT is an emerging optical imaging technology based on inter-
ferometry using a near infra-red light source. It exploits differences
in the refractive index in the skin to create vertically sectioned im-
ages in vivo, in real time, and has a relatively high depth of pen-
etration, allowing dermal lesions to be delineated (Olsen 2015).
OCT is considered to be particularly useful for the differentia-
tion of non-pigmented lesions. Pigmented lesions produce regular
scattering patterns which inhibit the differentiation of malignant
from benign lesions (Olsen 2015; Gambichler 2015). The use
of high-frequency ultrasound has been advocated in diagnosing
a range of skin conditions, including skin cancer, infection, and
inflammatory conditions (Kleinerman 2012), with malignant le-
sions reportedly appearing as hypoechogenic areas surrounded by
a hyperechogenic dermis. Melanomas in particular also reportedly
appear homogenous and with well-defined margins (e.g. Harland
2000). CADor artificial intelligence-based techniques process and
manipulate lesion data using predefined algorithms to identify the
features that discriminate malignant from benign lesions (Rajpara
2009; Esteva 2017). These techniques have been incorporated
into commercially available hand-held devices for ease of use in a
clinic setting, including SIAscopy (Moncrieff 2002;Walter 2012),
MelaFind (Monheit 2011; Wells 2012; Hauschild 2014), and the
Nevisense Electrical Impedance Spectroscopy system (Malvehy
2014).However, CADhasmost commonly been applied to digital
dermoscopy images (Rajpara 2009; Esteva 2017).
We also did not assess histopathological confirmation following
lesion excision, because it is the established reference standard for
skin cancer diagnosis andwill be one of the standards againstwhich
the index tests are evaluated in these reviews
Rationale
This series of reviews of diagnostic tests used to assist the clinical
diagnosis of BCC and cSCC, aims to identify the most accurate
approaches to diagnosis and toprovide clinical andpolicy decision-
makers with the highest possible standard of evidence on which
to base decisions. With the increasing availability of a wider range
of tests, there is a need to differentiate and appropriately triage
keratinocyte skin cancers to avoid sending too many people with
benign or low risk lesions for a specialist opinion and possible
excision or biopsy, while notmissing those people who have lesions
that require treatment.
Although a set of billing codes for the USA have been agreed since
January 2016 (Rajadhyaksha 2017), RCM is not recommended
for routine use in the UK (Edwards 2016), Australia (Guitera
2017), or New Zealand (Sobarun 2015). To date, the use of RCM
has been limited by expense (in terms of both equipment and
staff time) and the need for specialised training. Some studies have
demonstrated high sensitivity and specificity among experienced
RCM users, however, in at least one study, the accuracy of the
group on average was higher than that of any one individual ob-
server (Farnetani 2015). Our own systematic review of 18 studies
of RCM for the diagnosis of melanoma suggested that although
RCM may augment diagnostic sensitivity when used in conjunc-
tion with clinical inspection and dermoscopy, its main contribu-
tion was an increase in specificity, reducing the number of people
receiving unnecessary surgery by up to three-quarters compared
to dermoscopy (Dinnes 2018a).
Available systematic reviews of RCM for keratinocyte skin can-
cers are limited by out of date searches and methods. Xiong 2016
failed to consider differences in study populations and varying
definitions of the target condition, and used an out of date meta-
analytic approach. Mogensen 2007 did not report the use of sys-
tematic methods for study inclusion or extraction and did report
undertaking quality assessment, while Edwards 2016 focused on
selected studies considered to be more applicable to a UK setting.
In this rapidly advancing field, there is a need for an up-to-date
analysis of the accuracy of RCM for the diagnosis of keratinocyte
skin cancer.
This review follows a generic protocol which covers the full series
of Cochrane DTA Reviews for the diagnosis of keratinocyte skin
cancer (Dinnes 2015a). The Background andMethods sections of
this review therefore use some text that was originally published
in the protocol (Dinnes 2015a) and text that overlaps some of our
other reviews (Dinnes 2018a; Dinnes 2018b).
O B J E C T I V E S
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To determine the diagnostic accuracy of RCM for the detection
of BCC, cSCC, or any skin cancer in adults with any suspicious
lesion and lesions that are difficult to diagnose (equivocal); and to
compare its accuracy with that of usual practice (visual inspection
or dermoscopy, or both).
Accuracy was estimated separately according to the point in the
clinical pathway at which RCM was evaluated:
• in participants with any suspicious lesion, where RCM
might have been used as an alternative to dermoscopy or to
supplement visual inspection alone;
• in participants with equivocal (or more difficult to
diagnose) lesions in whom a clear management decision could
not be made following visual inspection and dermoscopy, where
RCM might have been used as an addition to visual inspection
or dermoscopy, or both.
Studies that did not clearly fit into either of these two groups
were considered as ’other lesion’ studies. The terms equivocal and
’difficult to diagnose’ have been used, and should be interpreted,
interchangeably throughout this review.
Secondary objectives
To determine the diagnostic accuracy of RCM for the detection of
any skin cancer in adults, where keratinocyte skin cancers made up
at least 50% of included skin cancers, and to compare its accuracy
with visual inspection or dermoscopy, or both.
Accuracy was estimated separately according to the point in the
clinical pathway at which RCM was evaluated:
• where it might have been used as an alternative to
dermoscopy in participants with any lesion suspicious for
melanoma;
• where it might have been used as an addition to visual
inspection or dermoscopy, or both, in participants with
equivocal lesions in whom a clear management decision could
not be made following visual inspection and dermoscopy alone.
For the detection of BCCor cSCC (the primary target conditions):
• to compare the accuracy of RCM to dermoscopy where
both tests were evaluated in the same studies (direct test
comparisons);
• to determine the diagnostic accuracy of individual
algorithms for RCM;
• to determine the effect of observer experience.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity
for investigation across our series of reviews, as outlined in our
generic protocol (Dinnes 2015a) and described in Appendix 3;
however, our ability to investigate these was necessarily limited by
the available data on each individual test reviewed.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the
result of the index test with that of a reference standard, including
the following:
• studies where all participants received a single index test
and a reference standard;
• studies where all participants received more than one index
test(s) and reference standard;
• studies where participants were allocated (by any method)
to receive different index tests or combinations of index tests and
all received a reference standard (between-person comparative
(BPC) studies);
• studies that recruited series of participants unselected by
true disease status (referred to as case series for the purposes of
this review);
• diagnostic case-control studies that separately recruited
diseased and non-diseased groups (see Rutjes 2005);
• both prospective and retrospective studies; and
• studies where previously acquired clinical or dermoscopic
images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2×2 con-
tingency data, or if they included fewer than five cases of BCC
or cSCC or fewer than five benign lesions. The size threshold of
five is arbitrary. However such small studies are unlikely to add
precision to estimate of accuracy.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with lesions suspicious for skin can-
cer.
We excluded studies that recruited only participants with malig-
nant diagnoses and studies that compared test results in partici-
pants with malignancy compared with test results based on ’nor-
mal’ skin as controls, due to the bias inherent in such comparisons
(Rutjes 2006).
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We excluded studies conducted in children or which clearly re-
ported more than 50% of participants aged 16 years and under.
Index tests
We included studies evaluating RCM alone, or RCM in compar-
ison to usual practice (visual inspection or dermoscopy, or both).
We included all established algorithms or checklists to assist diag-
nosis by RCM. We included studies developing new algorithms
or methods of diagnosis (i.e. derivation studies) if they:
• used a separate independent ’test set’ of participants or
images to evaluate the new approach, or
• investigated lesion characteristics that had previously been
suggested as associated with BCC or cSCC and the study
reported accuracy based on the presence or absence of particular
combinations of characteristics.
We excluded studies if they:
• used a statistical model to produce a data driven equation,
or algorithm based on multiple diagnostic features, with no
separate test set;
• used cross-validation approaches such as ’leave-one-out’
cross-validation (Efron 1983);
• evaluated the accuracy of the presence or absence of
individual lesion characteristics or morphological features, with
no overall diagnosis of malignancy.
There were no exclusions made according to test observer.
Target conditions
Two primary target conditions were defined as the detection of:
• basal cell carcinoma (BCC), including all subtypes;
• invasive cutaneous squamous cell carcinoma (cSCC) (we
did not consider cSCC in situ or Bowen’s disease as disease
positive).
An additional definition of the target condition was considered in
secondary analysis, the detection of:
• any skin cancer, including BCC, cSCC, melanoma, or any
rare skin cancer (e.g. Merkel cell cancer), as long as skin cancers
other than melanoma made up more than 50% of the disease
positive group. Data from studies in which melanoma accounted
for more than 50% of skin cancers were included in the review of
RCM for the diagnosis of melanoma (Dinnes 2018a).
Reference standards
The ideal reference standard was histopathological diagnosis in
all eligible lesions. A qualified pathologist or dermatopathologist
should have performed histopathology. Ideally, reporting should
have been standardised detailing aminimumdataset to include the
type of skin cancer (BCC, cSCC) and subtype of BCC and may
also have referred to the TNM (tumour, node, and metastasis)
classification of staging for cSCC (Royal College of Pathologists
2014). We did not apply the reporting standard as a necessary
inclusion criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of
participants undergoing the index test) was of concern given that
lesion excision or biopsy were unlikely to be carried out for all
benign-appearing lesions within a representative population sam-
ple. Therefore, we accepted clinical follow-up of benign-appear-
ing lesions as an eligible reference standard, while recognising the
risk of differential verification bias (as misclassification rates of
histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry fol-
low-up and ’expert opinion’ with no histology or clinical follow-
up. Cancer registry follow-up is considered less desirable than ac-
tive clinical follow-up, as it is not carried out within the control of
the study investigators. Furthermore, if participant-based analyses
as opposed to lesion-based analyses are presented (as for cancer
registry follow-up), it may be difficult to determine whether the
detection of a malignant lesion during follow-up was the same
lesion that originally tested negative on the index test.
All of the abovewere eligible reference standardswith the following
caveats:
• all study participants with a final diagnosis of the target
disorder must have had a histological diagnosis, either
subsequent to the application of the index test or after a period
of clinical follow-up, and
• at least 50% of all participants with benign lesions must
have either had a histological diagnosis or clinical follow-up to
confirm benignity.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
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MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 4). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed on MEDLINE. The Information Special-
ist devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies:
• MEDLINE via Ovid (from 1946);
• MEDLINE In-Process & Other Non-Indexed Citations via
Ovid; and
• Embase via Ovid (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) 2016, Issue 7, in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR)
2016, Issue 8, in the Cochrane Library;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE) 2015, Issue 2;
• CRD HTA (Health Technology Assessment) database
2016, Issue 3; and
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We screened relevant systematic reviews identified by the searches
for their included primary studies, and included any missed by
our searches. We checked the reference lists of all included papers,
and subject experts within the author team reviewed the final list
of included studies. There was no electronic citation searching.
Data collection and analysis
Selection of studies
At least one review author (JD or NC) screened titles and ab-
stracts with any queries discussed and resolved by consensus. A
pilot screen of 539MEDLINE references showed good agreement
(89% with a kappa of 0.77) between screeners. Primary test ac-
curacy studies and test accuracy reviews (for scanning of reference
lists) of any test used to investigate suspected melanoma, BCC, or
cSCC were included at initial screening. Both a clinical reviewer
(from one of a team of 12 clinician reviewers) and a methodolo-
gist reviewer (JD or NC) independently applied inclusion criteria
to all full text articles (Appendix 3). We resolved disagreements
by consensus or by a third party (JDD, CD, HW, and RM). We
contacted authors of eligible studies when insufficient data were
presented to allow for the construction of 2×2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer
(JD, NC or LFR) independently extracted data concerning details
of the study design; participants; index test(s) or test combinations;
and criteria for index test positivity, reference standards, and data
required to populate a 2×2 diagnostic contingency table for each
index test using a piloted data extraction form. We extracted data
at all available index test thresholds. We resolved disagreements
by consensus or by a third party (JDD, CD, HW, and RM). We
entered data into Review Manager 5 (Review Manager 2014).
We contacted authors of included studies where information re-
lating to the diagnostic threshold was missing. We contacted au-
thors of conference abstracts published from 2013 to 2015 to ask
whether full data were available. If we identified no full paper, we
marked conference abstracts as ’pending’ and will revisit them in
a future review update.
Dealing with multiple publications and companion papers
Where we identified multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If this contact with authors was unsuccessful, we used
the most complete and up-to-date data source where possible.
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Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 6). The modified QUADAS-2 tool was pi-
loted on a small number of included full text articles. One clinical
and one methodologist reviewer (JD, NC, or LFR) independently
assessed quality for the remaining studies; we resolved any dis-
agreement by consensus or by a third party where necessary (JDD,
CD, HW, and RM).
Statistical analysis and data synthesis
For the detection of each definition of the target condition, we
conducted separate analyses according to the point in the clinical
pathway that RCMwas applied. There were three groups of studies
formed:
• RCM used in participants with any lesion suspicious for
skin cancer (i.e. no attempt to exclude cancers diagnosed as
obvious BCCs or SCCs or as clearly benign on visual inspection
or dermoscopy was described (denoted as studies in ’any
suspicious lesion’));
• RCM used as an addition to dermoscopy in participants
with equivocal lesions in whom a clear management decision
could not be made following visual inspection and dermoscopy
(denoted as studies in ’equivocal’ lesions);
• ’Other’ studies which did not fit into either of these
categories.
Our unit of analysis for all analyses was the lesion rather than the
participant. This is because 1. in skin cancer initial treatment is
directed to the lesion rather than systemically (thus it is important
to be able to correctly identify cancerous lesions for each person),
and 2. it is the most common way in which the primary studies
reported data. Although there was a theoretical possibility of cor-
relations of test errors when the same people contributed data for
multiple lesions, most studies included very few people with mul-
tiple lesions and any potential impact on findings was likely to be
very small, particularly in comparison with other concerns regard-
ing risk of bias and applicability. For each analysis undertaken, we
included only one dataset per study to avoid overcounting of le-
sions. Where an individual study assessed multiple thresholds, we
selected datasets for correct diagnosis of each type of malignancy
as opposed to data for the decision to excise lesions. If studies re-
ported data for multiple observers, we used data from the most ex-
perienced observer, and used data for a single observer’s diagnosis
in preference to a consensus or mean across observers. If we were
unable to choose a dataset based on the above ’rules,’ we made a
random selection of one dataset per study.
For each index test, algorithm or checklist under consideration,
we plotted estimates of sensitivity and specificity on coupled for-
est plots and in receiver operating characteristic (ROC) space.
For tests that reported commonly used thresholds, we estimated
summary operating points (summary sensitivities and specificities)
with 95% confidence and prediction regions using the bivariate
hierarchical model (Chu 2006; Reitsma 2005). Where there were
inadequate data available for the model to converge, we simplified
the model, first by assuming no correlation between estimates of
sensitivity and specificity and second by setting estimates of near
zero variance terms to zero (Takwoingi 2017). Where all studies
reported 100% sensitivity (or 100% specificity), we summed the
number with disease (or no disease) across studies and used this to
compute a binomial exact 95% CI. We assessed heterogeneity in
estimates of sensitivity and specificity by inspection of the magni-
tude and statistical significance of the estimates of variance terms
in the bivariate model.
We included data on the accuracy of visual inspection or der-
moscopy, to allow comparisons of tests, only if reported in the
studies of RCM due to the known substantial unexplained hetero-
geneity in all studies of the accuracy of these tests (Dinnes 2018a).
We made comparisons between tests using RCM data from all
RCMstudies, and thenonly usingRCMdata from studies that also
reported visual inspection or dermoscopy data for the same par-
ticipants to enable a robust direct comparison (Takwoingi 2013).
For computation of likely numbers of true-positive, false-posi-
tive, false-negative, and true-negative findings in the ’Summary
of findings’ tables, we applied summary sensitivity and specificity
estimates to lower, median, and upper quartiles of the prevalence
observed in the study groups.
We fitted bivariate models using the meqrlogit command in
STATA 13.
Investigations of heterogeneity
We initially examined heterogeneity between studies by visually
inspecting the forest plots of sensitivity and specificity and sum-
mary ROC plots. Where there were a sufficient number of studies,
we performed meta-regression by adding the potential source of
heterogeneity as a covariate to a hierarchical model.
Sensitivity analyses
We performed no sensitivity analyses.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for
detecting funnel plot asymmetry (Deeks 2005), we performed no
tests to detect publication bias.
R E S U L T S
Results of the search
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The search identified and screened 34,517 unique references for
inclusion. Of these, 1051 full text papers were reviewed for eligi-
bility for any one of the suite of reviews of tests to assist in the
diagnosis of melanoma or keratinocyte skin cancer. Of the 1051
full text papers assessed, 848 were excluded from all reviews in our
series (see Figure 5 PRISMA flow diagram of search and eligibility
results).
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Figure 5. PRISMA flow diagram.
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Of the 83 studies tagged as potentially eligible for the two RCM
reviews, 22 publications were included, reporting 22 individual
studies: 10 in this review and 18 in the review of RCM for the
detection of melanoma (six were included in both). Reasons for
exclusion included publications not being primary test accuracy
studies (14 studies); lack of test accuracy data (six studies); be-
cause they were derivation studies developing new algorithms or
approaches to diagnosis without the use of separate training and
test sets of data (five studies); included ineligible populations (e.g.
including only malignant lesions (six studies); did not assess eligi-
ble target conditions or did not adequately define the target con-
dition (20 studies); inadequate sample size (15 studies); assessed
the accuracy of individual RCM characteristics (four studies); or
used ineligible reference standards (i.e. less than 50% of benign
group with final diagnosis established by histology or follow-up;
four studies). A list of the 73 studies excluded from this review
with reasons for exclusion is provided in the Characteristics of
excluded studies table, with a list of all studies excluded from the
full series of reviews available as a separate pdf (please contact
skin.cochrane.org for a copy of the pdf ).
We contacted the corresponding authors of six publications and
asked them to supply further information for the purposes of this
review. To date, responses have been received from only one au-
thor to allow study inclusion (Incel 2015). In addition, Professor
Pellacani provided information on lesion overlap between several
identified studies that were coauthored by him.
This review reported on 11 cohorts of participants with lesions
suspected of skin cancer, published in 10 study publications, pro-
viding 91 datasets for RCM and four for usual practice (visual
inspection (one cohort) or dermoscopy (three cohorts)). A total
of 2037 lesions with 464 BCCs were included in the 11 datasets
reporting data for BCC, and 834 lesions with 71 cSCCs were
included in the four datasets reporting data for cSCC. The total
number of study participants could not be estimated due to lack of
reporting in study publications. The Pellacani 2014 study was split
into two cohorts for the purposes of this review: one cohort of le-
sions equivocal on dermoscopy denoted as the RCM ’consultation’
group by the study authors (Pellacani 2014a (cons)); and the other
cohort of lesions recommended for excision on the basis of clear
cut clinical or dermoscopic findings, denoted as the RCM ’doc-
umentation’ group by the study authors (Pellacani 2014b (doc)).
There is a description of the various algorithms and thresholds
used for diagnosis across the studies in Appendix 7.
Methodological quality of included studies
The overallmethodological quality of all 11 included study cohorts
is summarised in Figure 6 and Figure 7. Studies were generally at
high or unclear risk of bias across all domains apart from the index
test and of high or unclear concern regarding applicability of the
evidence.
Figure 6. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 7. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Almost two-thirds of cohorts were at high (four cohorts) or unclear
(three cohorts) risk of bias for participant selection due to exclu-
sion of poor-quality images (three cohorts), use of a case-control
type design (one cohort) or unclear participant selection (three
cohorts). All cohorts were at high (eight cohorts) or unclear (three
cohorts) concern regarding applicability of included participants
and setting, due to restricted study populations (with four studies
including only participants with lesions suspected of melanoma,
two including only those with high clinical suspicion of BCC, and
two with more narrowly defined populations such as nodular le-
sions or proliferative lesions) and inclusion of multiple lesions per
participant (five cohorts). Eight of the 11 cohorts included lesions
selected for excision based on the clinical or dermoscopic diagnosis
or selected retrospectively from histopathology databases; this was
not considered of high concern regarding applicability for RCM
studies as the primary role for RCM is to reduce unnecessary ex-
cisions.
All cohorts were at low risk of bias in the index test domain.
Over half of studies were high concern for the applicability of
the index test (seven cohorts), due to remote RCM interpretation
(five cohorts), blinding to clinical information (three cohorts),
presentation of consensus diagnoses only (one cohort), lack of
detail regarding the diagnostic threshold used (two cohorts), or
interpretation by a non-expert observer (two cohorts). It is of note
that eight of the 11 cohorts were produced by, or in collaboration
with, the same expert research team, led by Professor Pellacani
which may further reduce the generalisability of results.
One cohort was at low risk of bias for the reference standard, two at
high risk due to inadequate reference standards (greater than 20%
of the disease negative group with final diagnosis by follow-up or
expert opinion), and eight at unclear risk due to unclear blinding
of the reference standard to the RCM result. None of the cohorts
reported blinding of histology to the referral diagnosis (based on
clinical examination or dermoscopy), but this was not incorpo-
rated into the overall risk of bias for this domain. For the applica-
bility of the reference standard, one cohort was at high risk due to
the use of expert observer diagnosis as the reference standard and
nine cohorts were unclear regarding histopathology interpretation
by an experienced histopathologist or by a dermatopathologist.
For participant flow and timing, three cohorts were at low risk of
bias, five at high risk, and three at unclear risk. Three cohorts did
not use the same reference standard for all participants (differential
verification), seven cohorts were unclear on the interval between
the application of the index test and excision for histology, and four
cohorts did not include all participants in the analysis primarily
due to technical difficulties in imaging.
Findings
1. Target condition: basal cell carcinoma
In this section, we presented the results for studies of RCM versus
visual inspection or dermoscopy for the target condition of BCC,
according to the study population: studies in participants with
any lesions suspicious for melanoma versus those in participants
with equivocal lesions. The included studies used a number of
different approaches toRCMdiagnosis; see Appendix 7 for details.
Appendix 8 provides summary characteristics of studies. Table 1
presents the results for the primary analyses. Figure 8 gives forest
plots of study data for each analysis in this tablewith studies plotted
in ROC space in Figure 9 and Figure 10. Table 2 and Figure 11
compare results between observers.
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Figure 8. Forest plot of tests: RCM for the detection of BCC in any suspicious lesion (top), equivocal lesions
(centre), other lesion (bottom) populations. CI: confidence interval; FN: false negative; FP: false positive; TN:
true negative; TP: true positive.
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Figure 9. ROC Plot of tests: RCM for the detection of BCC in any suspicious lesion, equivocal lesions, other
lesion populations.
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Figure 10. ROC Plot of tests: reflectance confocal microscopy versus dermoscopy in equivocal lesions
(Witkowski 2016). BCC: basal cell carcinoma; CI: confidence interval.
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Figure 11. Forest plot of accuracy of reflectance confocal microscopy to detect basal cell carcinoma (BCC)
by experience (separately for in-person and image-based studies). CI: confidence interval; FN: false negative;
FP: false positive; TN: true negative; TP: true positive.
Any suspicious lesion
The following section documents studies where RCM appeared
to have been evaluated in participants with any lesion scheduled
for excision. These populations are likely to include both clinically
or dermoscopically obvious BCCs, along with a proportion of
more difficult to diagnose (equivocal) lesions so that RCM was
being evaluated as an addition to visual inspection alone or visual
inspection with dermoscopy.
Four studies provided data for the detection of BCC with RCM
(Curchin 2011; Guitera 2012; Pellacani 2014b (doc); Rao 2013).
A total of 912 lesions were included with 107 cases of BCC. One
study provided data for expert and non-expert observers; how-
ever, only 284 of the 334 included lesions were evaluated by both
readers (Rao 2013). The total number of participants could not
be reported due to lack of reporting in two of the four studies
(Guitera 2012; Rao 2013; Guitera 2012 reported overall number
of participants but not the number with lesions included in the
test set of data).
All studies were case series and undertaken in secondary or spe-
cialist clinic settings. Lesions were scheduled for excision report-
edly for cosmetic or medical reasons (Rao 2013), reasons not
reported (Curchin 2011), to rule out an ’epithelial tumour’ or
melanoma (Guitera 2012), or due to clinical or dermoscopy suspi-
cion of melanoma (Pellacani 2014b (doc)). Three studies included
any type of lesion, and one restricted to pigmented lesions only
(Pellacani 2014b (doc)). Sample sizes ranged from 50 to 356 le-
sions. The median lesion to participant ratio in three studies was
1.19 (range 1.07 to 1.20). The mean prevalence of BCC was 13%
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(range 8% to 18%); themean prevalence of anymalignancy (BCC,
cSCC, or melanoma) was 34% (range 22% to 56%). All studies
also reported data for the diagnosis of melanoma (Dinnes 2018a).
Studies generally included a varied spectrum of benign lesions in-
cluding benign melanocytic naevi (Guitera 2012; Pellacani 2014b
(doc); Rao 2013), Spitz naevi (Guitera 2012; Pellacani 2014b
(doc); Rao 2013), and seborrhoeic or actinic keratoses (Guitera
2012; Pellacani 2014b (doc); Rao 2013), or both. All studies made
the reference standard diagnosis by histology alone (i.e. all lesions
either excised or biopsied).
All four studies used the Vivascope 1500 imaging system; three
reporting the use of dermoscopic images to help guide acquisition
of RCM images (Curchin 2011; Guitera 2012; Rao 2013). The
studies reported diagnosis for a single observer rather than for a
consensus of observers or mean value.OnlyGuitera 2012 reported
observer qualifications (dermatologists). Three studies presented
data for expert observers (Guitera 2012; Pellacani 2014b (doc);
Rao 2013) and one for novice observers (Curchin 2011). Studies
undertook diagnosis in person with real-time interpretation of
RCM images (Curchin 2011; Pellacani 2014b (doc)), or remotely
based on RCM images alongside the dermoscopic image of the
same lesion (Guitera 2012; Rao 2013). Rao 2013 also presented
data for in-person diagnosis by a less experienced observer but this
was not included in the primary analysis for detection of BCC.
One study developed a new algorithm for detection of melanoma
and BCC (data for the BCC element are reported here) (Guitera
2012), and the other three reported data for the correct diagno-
sis of each type of malignancy (Curchin 2011; Pellacani 2014b
(doc); Rao 2013). Estimates of sensitivities ranged from 52% to
100% and specificities from 45% to 100% (Figure 8). The high
sensitivity of 100% and low specificity of 45% in Pellacani 2014b
(doc) appeared as outliers, all other studies having sensitivities at
or below 67% and specificities above 95% (Figure 9). Pellacani
2014b (doc) was the only study to restrict inclusion to pigmented
lesions, and all lesions had “consistent clinical and or dermoscopic
criteria for melanoma diagnosis;” it also included no cSCCs in the
disease negative group.
Summary sensitivity and specificity for the detection of BCC were
76% (95% CI 45% to 92%) and 95% (95% CI 66% to 99%)
(Table 1). Two studies incorrectly identified other skin cancers as
BCCs (8/114 false-positive diagnoses), including two melanomas
and two cSCCs in Guitera 2012 and four cSCCs in Rao 2013.
The other study which included cSCCs reported correct diagnosis
of all six cSCCs or cSCC precursors (Curchin 2011).
Equivocal lesion studies
We defined equivocal lesion studies as those in which RCM was
used in participants with equivocal lesions in whom a clear man-
agement decision could not be made following visual inspection
or dermoscopy (i.e. RCM was being evaluated as a potential ad-
dition to dermoscopy).
Three studies provided data for the detection of BCC with RCM
(Farnetani 2015; Pellacani 2014a (cons); Witkowski 2016), one
providing data for nine different observers (Farnetani 2015), and
one comparing the diagnosis of the same lesions with RCM and
using dermoscopic images (Witkowski 2016). A total of 668 le-
sions were included with 148 cases of BCC; the total number of
participants could not be reported due to lack of reporting in two
studies.
All studies were case series, two of which reinterpreted previously
acquired RCM images (Farnetani 2015; Witkowski 2016), and
were undertaken in secondary or specialist clinic settings. Two
studies included lesions suspected of being melanoma. Farnetani
2015 included any clinically equivocal lesion excised due to clin-
ical or dermoscopic suspicion of melanoma, and Pellacani 2014a
(cons) included pigmented lesions from participants requesting a
mole check or with suspicion of melanoma for which an outcome
decision could not be reached based on clinical or dermoscopic
criteria. One study included clinically equivocal ’pink’ cutaneous
lesionswith no pigmentation or containing less than 10%pigment
and the absence of pigment network (Witkowski 2016). Sample
sizes ranged from 100 to 308 lesions. The prevalence of BCC was
6% (Pellacani 2014a (cons)), 15% (Farnetani 2015), and 44%
(Witkowski 2016), and prevalence of any malignancy was 8% for
BCC, 35% for cSCC, and 53% for melanoma (only Witkowski
2016 included any cSCC). Two studies also reported data for the
diagnosis of melanoma (Farnetani 2015; Pellacani 2014a (cons);
see also Dinnes 2018a). Studies included a varied spectrum of be-
nign lesions, Farnetani 2015 and Pellacani 2014a (cons) including
predominantly benign melanocytic naevi andWitkowski 2016 in-
cluded a relatively larger proportion of benign keratotic lesions and
dermatofibromas (Appendix 8). Two studies made the reference
standard diagnosis by histology alone (Farnetani 2015;Witkowski
2016); Pellacani 2014a (cons) reported histological diagnosis for
the 81 lesions initially recommended for excision, with sequential
digital follow-up in the remaining 74% (227/308) of lesions; 28
of these (all found to be benign) were later excised due to changes
identified on follow-up.
All studies used the Vivascope 1500 imaging system and re-
ported diagnosis for single observers, with Farnetani 2015 also
reporting the mean across nine observers and for the majority
diagnosis (five of nine evaluators in agreement). Observers were
dermatologists (Farnetani 2015), assumed to be dermatologists
(Witkowski 2016), or RCM described as conducted in a ’confocal
unit’ (Pellacani 2014a (cons)).Diagnosiswas undertaken inperson
with real-time interpretation of RCM (Pellacani 2014a (cons)) or
remotely based on RCM images either alongside the dermoscopic
image of the same lesion (Farnetani 2015), or blinded to all other
clinical information (Witkowski 2016).
All three studies reported data for observer diagnosis of BCC. Es-
timates of sensitivities ranged from 85% to 100% and specificities
from 76% to 94% (Figure 8). The high specificity of 94% (95%
CI 89% to 97%) in Witkowski 2016 appeared as an outlier (non-
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overlapping CIs), the other two studies having specificities of 76%
(95% CI 66% to 85%) (Farnetani 2015) and 79% (95% CI 73%
to 83%) (Pellacani 2014a (cons)). Of note, Witkowski 2016 had a
markedly different participant population to the other two studies,
including only non-pigmented lesions with a markedly different
spectrum of lesion types (see above).
Summary sensitivity and specificity for the detection of BCC were
94% (95% CI 79% to 98%) and 85% (95% CI 72% to 92%)
(Table 1). Two studies incorrectly identified other skin cancers as
BCCs (15/91 false-positive diagnoses) including 14 melanomas
in Farnetani 2015 and one cSCC in Witkowski 2016.
Witkowski 2016 also presented data for the diagnosis of non-pig-
mented lesions based on the dermoscopic image alone (different
observers interpreting the RCM and dermoscopic images). Sen-
sitivity and specificity estimates were almost identical, with test
sensitivity of 85% (95% CI 77% to 91%) for both tests and speci-
ficity of 94% (95% CI 89% to 97%) for RCM compared to 92%
(95% CI 87% to 96%) for dermoscopy (Table 1; Figure 10).
Analyses by algorithms used to assist reflectance confocal
microscopy
The 11 included cohorts of lesions provided 12 datasets evaluating
the accuracy of different approaches to diagnosis with RCM for
the detection of BCC. Appendix 7 provides a description of these
approaches.
Only one eligible study used a formally developed algorithm for the
detection of BCC in an ’any suspicious lesion’ population. Guitera
2012 randomly allocated lesions to a training set for algorithm
development and a test set for validation to develop a new two-step
algorithm for the detection of melanoma and BCC. Lesions were
predominantly melanocytic or suspicious for BCC. Applying the
features independently significant for BCC, sensitivity was 65%
(95% CI 51% to 78%) and specificity was 95% (95% CI 92%
to 97%). These results were largely similar to those of the other
studies in ’any suspicious lesion’ (Figure 8), all of which reported
observers’ correct diagnosis of BCC. All data for ’equivocal lesion’
populations was also based on observers’ correct diagnosis of BCC
without the use of any formal algorithm.
Two studies reported accuracy for features found to be indepen-
dently significant for BCC but did not use a separate training
set to ascertain the relevant features (Castro 2015; Longo 2013).
Two studies selected lesion characteristics thought to assist the
correct diagnosis of BCC based on previously published literature
(Appendix 7) (Incel 2015; Nori 2004). All four studies were clas-
sified as ’other lesion population’ studies, and are covered in more
detail below. All studies reported sensitivities and specificities at
or above 90%, apart from specificities of 78% (95% CI 40% to
97%) reported in Castro 2015, which included only nine ’benign’
lesions, and of 78% (95% CI 67% to 87%) in Nori 2004, which
reported only that control group lesions had a ’range of common
diagnoses’ to BCC (Figure 8).
Analyses by observer experience
The 11 included studies provided 19 datasets evaluating the ac-
curacy of observers with different levels of expertise; nine datasets
coming from the same study (Farnetani 2015).
Figure 11 provides forest plots of all studies by observer experience,
separately for in-person and image-based studies. Table 2 presents
meta-analytical estimates for each group. Data for two of the nine
observers (one for high experience and one for low experience)
were randomly sampled from Farnetani 2015. One further study
provided a comparison of a less experienced (in-person diagno-
sis) observer compared to a more experienced (but image-based
diagnosis) observer; however, the two observers did not examine
the same lesions (overlap of 284/334 lesions) (Rao 2013). We did
not formally make any comparisons between subgroups due to the
small number of studies available.
Seven cohorts presented data for observers judged to be expert or
experienced in RCM: three were based on in-person evaluations
(Pellacani 2014a (cons); Pellacani 2014b (doc)), or assumed to be
in person (Castro 2015); four were from image-based evaluations,
two where observers were provided with the dermoscopic image
of the same lesion (Farnetani 2015; Rao 2013), and two where
observers were blinded to all clinical information (Guitera 2012;
Longo 2013). The pooled sensitivity for the seven datasets was
98% (95% CI 74% to 100%) and pooled specificity was 87%
(95% CI 71% to 95%) (Table 2). Sensitivities were at or above
90% in all studies apart from Guitera 2012 (65%, 95% CI 51%
to 78%) and Rao 2013 (52%, 95% CI 32% to 71%). Specificities
were more variable (45% to 98%), likely due to variations in the
spectrum of disease (Figure 11).
Four cohorts presented for observers judged to be less experienced
or novice: twowere based on in-person evaluations (Curchin 2011;
Rao 2013), and two were image based, one providing observers
with the dermoscopic image of the same lesion (Farnetani 2015),
and one blinding observers to all clinical information (Nori 2004).
The pooled sensitivity for the four datasets was 85% (95% CI
69% to 93%) and specificity was 91% (95% CI 81% to 96%)
(Table 2).
Two studies did not report the experience of RCM observers (Incel
2015; Witkowski 2016) (Table 2).
Investigations of heterogeneity
We were unable to undertake investigations of heterogeneity for
other characteristics listed in the protocol due to lack of data.
2. Target condition: cutaneous squamous cell
carcinoma
Two studies reported data for RCM for the target condition of
cSCC: one conducted in participants with any lesion suspicious
for melanoma (Rao 2013), and one in comparison to dermoscopy
participants with equivocal lesions (Witkowski 2016). Appendix
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8 provides summary characteristics of studies. Table 3 presents
study results and Figure 12 presents forest plots of study data. Two
further studies present data for cSCC in ’other’ lesion populations
(see ’Other lesion populations’ section below).
Figure 12. Forest plot of tests: reflectance confocal microscopy for the detection of cSCC in any suspicious
lesion (top), equivocal lesions (centre), and other lesion (lower) populations. CI: confidence interval; FN: false
negative; FP: false positive; TN: true negative; TP: true positive.
Rao 2013 included lesions scheduled for excision for cosmetic or
medical reasons and presented results for the correct diagnosis of
cSCC for two observers with varying levels of experience based on
in-person diagnosis and interpretation of RCM images alongside
dermoscopic images. For the experienced observer assessing RCM
images (42/323 assessed were cSCC), sensitivity for the detection
of cSCC was 74% (95% CI 58% to 86%) and specificity was
92% (95% CI 88% to 95%). For the less experienced observer,
in-person RCM interpretation (39/318 assessed were cSCC) had
a lower sensitivity of 41% (95% CI 26% to 58%) and higher
specificity of 97% (95% CI 95% to 99%).
Witkowski 2016 included 260 clinically equivocal ’pink’ cuta-
neous lesions and presented results for the correct diagnosis of
cSCC (13 lesions) for one observer based on RCM image interpre-
tation and for another observer based on the dermoscopic image
alone; there was no other clinical information. Sensitivity was the
same for both tests 77% (95% CI 46% to 95%), and specificities
were almost identical at 98% for RCM (95% CI 96% to 100%)
and 99% for dermoscopy (95% CI 96% to 100%).
3. Target condition: any skin cancer
Four studies reported data for RCM for the target condition of any
skin cancer: two were conducted in participants with any lesion
suspicious for melanoma (Curchin 2011; Rao 2013), and two in
participants with equivocal lesions (Farnetani 2015; Witkowski
2016). Appendix 8 presents summary characteristics of studies.
Table 4 present study results and Figure 13 presents forest plots of
study data.
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Figure 13. Forest plot of tests: reflectance confocal microscopy for the detection of any skin cancer (KER) in
any suspicious lesion (top), equivocal lesions (centre), other lesion (lower) populations. CI: confidence interval;
FN: false negative; FP: false positive; TN: true negative; TP: true positive
Both studies in the any suspicious lesion group included lesions
scheduled for excision, with diagnosis undertaken in person by
a novice RCM reader (Curchin 2011), or remotely by an RCM
expert based on RCM images (Rao 2013). Both studies reported
data for the observer’s correct diagnosis of each malignancy, and
Rao 2013 reported data for the correct diagnosis of each type of
malignancy and for the decision to excise a lesion. Rao 2013 also
reported data for in-person evaluation with RCM by a less experi-
enced observer (data not included due to a prior stated preference
for more experienced observer data). A total of 373 lesions were
included with 100 skin cancers (22 melanoma, 36 BCC, and 42
cSCCs), pooled sensitivity was 85% (95% CI 0.77% to 0.91%)
and specificity was 86% (95% CI 82% to 98%).
One of the two studies in equivocal lesions was conducted in
participants with lesions excised due to suspicion for melanoma
(Farnetani 2015), and one in non-pigmented or ’pink’ lesions
(Witkowski 2016). A total of 360 lesions were included with 175
malignant cases (32 melanomas, 129 BCCs (114 of which were
from the Witkowski 2016 dataset), 13 cSCCs, and one syringoid
eccrine carcinoma). Despite differences in the spectrum of in-
cluded lesions, results from the two studies were similar (Figure
13), and pooled sensitivity was 89% (95% CI 0.82% to 0.94%)
and specificity was 85% (95% CI 75% to 92%).
One study from each of these two groups provided data both for
correct diagnosis of each malignancy and for the decision to excise
suspicious lesions (Rao 2013; Witkowski 2016). Figure 14 and
Figure 15 demonstrate the trade-off between higher sensitivity and
lower specificity from the lower excision threshold.
33Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 14. ROC plot of tests: reflectance confocal microscopy for the detection of any skin cancer (KER) for
correct diagnosis of each malignancy and decision to excise a lesion (image-based evaluations).
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Figure 15. ROC plot of tests: reflectance confocal microscopy for the detection of any skin cancer (KER) for
correct diagnosis of each malignancy and decision to excise a lesion (in-person evaluations).
4. Other lesion populations
Four evaluations of RCM in other study populations were identi-
fied. Appendix 8 provides summary characteristics of studies, with
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forest plots in Figure 8 and ROC plots in Figure 9.
Two studies included lesions with a high index of suspicion for
BCC (Castro 2015; Nori 2004). Castro 2015 included excised
lesions suspicious for BCC based on clinical and dermoscopic ex-
amination and that were amenable to RCM examination using
a hand-held RCM probe (Vivascope 3000) to allow comparison
with the standard approach (Vivascope 1500); 83% (45/54) of
included lesions were histological confirmed to be BCC. The pres-
ence of RCM lesion characteristics selected from previous studies
was assessed; however, it was not clear whether this was an image-
based or in-person evaluation. Sensitivity was 100% (95%CI 92%
to 100%) using the Vivascope 1500 system compared to 93%
(95% CI 82% to 99%) using the Vivascope 3000, and specificity
estimates were both 78% (95% CI 40% to 97%). There were no
melanomas or cSCCs in this study.
Nori 2004 included 83 biopsy confirmedBCCs and a convenience
sample of non-BCC with ’range of common diagnoses;’ the preva-
lence of BCC was 55% (83/152). Diagnosis based on images ac-
quired using the Vivascope 1000 and based on the presence of
morphological RCM characteristics previously investigated by the
same group was compared to visual inspection of clinical images
(latter reported for only 105/152 lesions). Sensitivity and speci-
ficity were both higher using RCM (based on the presence of three
or more RCM criteria) compared to visual inspection: sensitivity
was 94% (95% CI 86% to 98%) with RCM versus 48% (95% CI
35% to 62%)with visual inspection and specificity was 78% (95%
CI 67% to 87%) with RCM compared to 62% (95% CI 46% to
75%) with visual inspection. Results for the four included cSCCs
could not be disaggregated from the benign diagnoses; there were
no melanomas.
Incel 2015 examined 122 non-pigmented suspected malignant le-
sions or proliferative skin lesions with a vascular structure on der-
moscopic examination with the hand-held Vivascope 3000 sys-
tem, using selected characteristics considered to be indicative of
BCC and characteristics considered to be indicative of cSCC. The
prevalence of BCC was 46% (56/122); of cSCC was 7% (9/122);
with keratoacanthoma, seborrhoeic, actinic keratosis, or Bowen’s
disease making up half of the benign group (29/57). Sensitivity
for the detection of BCC was 91% (95% CI 80% to 97%) and
specificity was 100% (95%CI 95% to 100%). All nine SCCswere
test negative (i.e. not mistaken for BCCs). Sensitivity for the de-
tection of cSCC was 82% (95% CI 48% to 98%) and specificity
was 96% (95% CI 91% to 99%). Similarly, this study mistook no
BCCs for SCCs.
Longo 2013 included 140 clinically nodular lesions that under-
went excision including 23 nodular melanomas (16%), 28 BCCs
(20%), six cSCC (5%), and nine with cutaneousmelanomametas-
tases (7.5%). An experienced dermatologist interpreted RCM im-
ages blinded to dermoscopy using RCM pattern analysis. Exclud-
ing non-evaluable results (including one BCC and one SCC), sen-
sitivities were 100% for detection of BCC and SCC, and specifici-
ties were 97% (95%CI 92% to 99%) for BCCand 100% (95%CI
97% to 100%) for SCC. For the detection of any malignant lesion
(excluding melanoma metastases), sensitivity was 100% (95% CI
93% to 100%) and specificity was 85% (95% CI 75% to 92%).
D I S C U S S I O N
Summary of main results
RCMhas been evaluated in a range of study populations and using
a number of different approaches to assist diagnosis. Most of the
data related to the detection of BCC, with few studies recruiting
sufficient numbers of participants with cSCC (i.e. five or more) to
allow accuracy to be reliably estimated. Both sensitivity and speci-
ficity for the detection of BCC appeared to vary with the spectrum
of included lesions. Sensitivity was relatively low in participants
with any suspicious lesion but was higher in studies of more se-
lected populations. Studies were generally at high or unclear risk of
bias across almost all domains and of high or unclear concern re-
garding applicability of the evidence, limiting the strength of con-
clusions that could be drawn. The Summary of findings presents
key results for the primary target conditions of BCC and cSCC.
For the detection of BCC in participants with any suspicious le-
sion, RCM summary sensitivity was 76% and specificity was 95%.
Applying these estimates to a hypothetical cohort of 1000 lesions at
themedian prevalence of BCCof 12.5%, the Summary of findings
showed that RCM would miss 30/125 BCCs with 44 false-posi-
tive diagnoses. On the evidence observed, only one of these false-
positive results might be amelanoma with up to twomisdiagnosed
cSCCs. The wide CIs for both estimates mean that the number
of BCCs missed could range from 10 to 69, and number of false
positives from nine to 298. A single cohort of lesions with a high
clinical or dermoscopic suspicion of being melanomas was respon-
sible for most of the variation in results (Pellacani 2014b (doc)).
The other studies in this group had sensitivities between 52% and
67% and specificities above 95%, which would correspond with
numbers of BCCs missed at the higher end of the 10 to 69 per
1000 range, and false positives at the lower end of the nine to 298
per 1000 range (with a corresponding reduction in the potential
for melanomas being misclassified as BCCs).
RCM sensitivity was higher (94%) for the detection of BCC in
participants with equivocal lesions, but with a lower specificity of
85%. Applying these estimates to a hypothetical cohort of 1000
lesions at the median prevalence of BCC of 15%, the Summary
of findings showed that RCM would miss 9/150 BCCs with 128
false-positive diagnoses. On the evidence observed for equivo-
cal lesions, there is a much greater potential for misdiagnosis of
melanomas as BCCs, with up to 19 of these false-positive results
potentially beingmelanomas. TheCIs around these estimates were
not as wide as for any suspicious lesion: the number of BCCs
missed at this disease prevalence could range between three and
32, and number of false positives from 68 to 238. The lowest
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sensitivity (85%) and highest specificity (94%) in this group were
produced from the cohort of non-pigmented lesions (Witkowski
2016), as opposed to the other two studies recruiting lesions equiv-
ocal for melanoma diagnosis.
There were insufficient data available to compare RCM with vi-
sual inspection or dermoscopy or to consider the effect of using
formally developed algorithms to assist RCM diagnosis of BCC.
However, there was some evidence of higher sensitivity frommore
experienced observers.
Data for the detection of cSCC were limited but suggested sensi-
tivity in the range of 74% to 77% with high specificity of 92% to
98%.
Strengths and weaknesses of the review
The strengths of this review included an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and methodol-
ogists, and contact with authors to allow study inclusion or clarify
data. A clear analysis structure according to patient pathway was
adopted to allow test accuracy in different study populations to be
estimated, and a detailed and replicable analysis of methodological
quality was undertaken.
Themain concerns for the reviewwere a result of the small number
of studies, variation in the spectrum of included lesions, and poor
reporting of primary studies, hindering the assessment of study
quality and limiting the conclusions that could be drawn from the
data. Despite some evidence of high sensitivity or specificity, or
both, depending on the study population, research in the field has
been dominated by a single expert group and results obtained from
a more typical range of specialists in different countries, health-
care systems, and settings are needed. Our analysis by observer
experience across algorithms and study populations lends support
to the consensus that experience and observer familiarity with the
diagnostic question is a key element of any diagnostic process that
requires interpretation by the human eye (Norman 2009). Only
one eligible study evaluated a formally developed algorithm to as-
sist RCM interpretation; however, we excluded four studies from
our review that examined individual RCM characteristics only or
did not use separate training and test sets of data (Amjadi 2011;
Eichert 2010; Peppelman 2015; Rishpon 2009). Further work in
this area may be warranted.
Given these limitations, our results should be considered as ex-
ploratory rather than conclusive. Our results are in contrast to
those of other recently published systematic reviews (Xiong 2016;
Edwards 2016), one of which was conducted as part of a technol-
ogy assessment report for NICE (Edwards 2016). However, our
review extends the time period searched for eligible studies from
2014 in Edwards 2016 and from 2015 in Xiong 2016, considers
the impact of different study populations and target conditions,
and uses currently recommended methods for DTA systematic re-
views (Deeks 2013). Xiong 2016 did not consider varying defini-
tions of the target condition in their primary analysis but pooled
all studies regardless of detection of melanoma, BCC, or SCC. In
a secondary analysis, three studies were pooled for the detection
of BCC, producing estimates of sensitivity of 91.7% (95% CI
86.5% to 95.4%) and specificity of 91.3% (95% CI 93.6% to
96.2%); two of the three studies with high percentages of BCC
lesions were included in our ’other population’ analysis (Castro
2015; Nori 2004); and one was excluded from this review due
to the presentation of individual RCM features for detection of
BCC rather than for an overall diagnosis (Peppelman 2013). The
Edwards 2016 review did not conduct a meta-analysis, instead se-
lecting studies considered to be more applicable to a UK setting.
Using the Castro 2015 study, which was included in our review
as an ’other lesion population’ study, economic modelling showed
RCM to be a dominant strategy when used in populations with a
high clinical suspicion of being BCCs in comparison to diagnostic
biopsy, whether used in lesions positive or equivocal for BCC on
dermoscopy. The potential for misdiagnosis of any melanomas or
cSCCs as BCCs does not appear to have been considered.
Applicability of findings to the review question
There were insufficient data available to compare the accuracy of
RCM with visual inspection or dermoscopy as planned. Similarly
there was a lack of data to assess the use different algorithms to
aid diagnosis. It is not clear how applicable the data included in
this review were regarding the routine use of RCM in a usual
clinic setting as opposed to a highly specialist centre with expert
RCM observers. Data were lacking regarding specific uses of the
test, for example, to confirm a clinical diagnosis of BCC before
initiation of non-surgical treatment. Most of the studies used the
current version of the only commercially available RCM system,
the Vivascope 1500. The use of remote image-based diagnosis
largely by RCM experts may restrict the transferability of results
to a clinical setting.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is unclear whether reflectance confocal microscopy (RCM) has
a role in clinical practice for the diagnosis of basal cell carcinoma
(BCC), although some studies suggest it has the potential to im-
prove diagnoses. There are as yet insufficient data to support its use
as a tool for avoidance of diagnostic biopsies in lesions with high
clinical suspicion of BCC. In populations with a wider spectrum
of lesions, there is potential for both missed BCCs and for misclas-
sification of benign lesions, or other malignant skin cancers such
as melanoma, as BCCs. Evidence for the detection squamous cell
carcinoma (cSCC) is even more scarce; however, there is a clear
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suggestion that cSCCs could be missed with RCM. Importantly,
data are lacking that compare RCM to usual practice (whether
with or without dermoscopy), such that the diagnostic impact of
RCM cannot be clearly estimated.
Implications for research
Further prospective evaluation of RCM in populations with a
high clinical suspicion of BCC is warranted. Research should be
conducted in a standard healthcare setting with a clearly defined
and representative population of participants with dermoscopi-
cally equivocal lesions. RCM results should be interpreted in a
usual care setting by healthcare staff representative of those who
would be likely to interpret images in practice, in order to confirm
the suggested increase in accuracy over dermoscopy. Amulticentre
approach would allow confirmation that results can be replicated
across centres and that the technology can be implemented across
a health service. Prospective recruitment of consecutive series of
participants, with test interpretation blinded to the reference stan-
dard diagnosis and with prespecified and clearly defined diagnos-
tic thresholds for determining test positivity is easily achieved.
Systematic follow-up of non-excised lesions avoids over-reliance
on a histological reference standard and allows results to be more
generalisable to routine clinical practice. A standardised approach
to diagnosis, and clear identification of the level of training and
experience required to achieve good results is also required. Any
future research study needs to be clear about the diagnostic path-
way followed by study participants prior to study enrolment, and
should conform to the updated Standards for Reporting of Diag-
nostic Accuracy (STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Castro 2015
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: NR
Country: Brazil and USA
Patient characteristics and set-
ting
Inclusion criteria: participants recruited were those presenting with ≥ 1 skin lesions that were
highly suspicious for BCC based on clinical and dermoscopic examination. All lesions underwent
biopsy
Setting: specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: clinical or dermatoscopic suspicion, or both
Setting for prior testing: unspecified
Exclusion criteria: poor-quality index test image; from discussion: “HH-RCM imaging was suc-
cessfully performed in all lesions in which imaging was attempted, while TWP-RCMwas technically
applicable in only 59% of lesions in which imaging was attempted.”
Sample size (participants): number eligible: 73
Sample size (lesions): number eligible: 92. number included: 54
Participant characteristics: mean age 65 years (range 30-89 years). Fitzpatrick phototype: 24
participants with type II; 8 participants with type III
Lesion characteristics: site reported for BCCs only - head/neck: 9, trunk: 26, upper limbs/shoulder:
4, lower limbs/hip: 6
Index tests RCM: Vivascope 3000; using 2 different ways of assessment using HH-RCM and TWP-RCM
No algorithm. Previously published RCM criteria assessed (cites Guitera 2012; Nori 2004; Agero
2006) and selected criteria chosen
Method of diagnosis: not clearly reported; may be in person. “All examinations, including clinical,
dermoscopic and RCM imaging, were made by a dermatologist experienced with RCM examination
(RPRC) with supervision by a skin cancer expert (GGR or HR).” However, also stated that, “All
RCM images were evaluated jointly by two readers blinded to the results of the histopathological
examination.” Not clear whether this was undertaken at the time of RCM examination or subse-
quently
Prior test data: clinical examination and dermoscopy. “All examinations, including clinical, der-
moscopic and RCM imaging, were made by a dermatologist experienced with RCM examination
(RPRC) with supervision by a skin cancer expert (GGR or HR).”
Diagnostic threshold: ≥ 3 RCM criteria present
Diagnosis based on: consensus (2 observers); (n = 2)
Observer qualifications: dermatologist
Experience in practice: high experience or ’expert’
Experiencewith index test:high experience/’expert’ users (not stated but both observers coauthored
studies developing RCM)
Other detail: attempted imaging with HH-RCM and TWP-RCM using a standardised protocol,
however, TWP-RCM imaging is restricted to anatomic locations that allow contact and is not
feasible in some anatomic locations such as the eyelids
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Castro 2015 (Continued)
Derivation aspect to study: images were evaluated for the presence of previously published RCM
criteria for identification of BCC; approach to selection of characteristics indicative of skin cancer
was not described
Characteristics selected: “at least one of the criteria had to be the presence of ’dark silhouettes’ or
’bright tumor islands’; these latter criteria denote the presence of neoplastic aggregates of BCC and
hence need to be observed in all cases identified as BCC by RCM.” Additional criteria assessed were:
• ’streaming’ polarisation of nuclei in neoplastic aggregates along the same axis of orientation;
• ’peripheral palisading’ of nuclei at the tumour islands’ periphery;
• dark ’peritumoral clefts’ around the tumour islands;
• fibrotic stroma with ’thickened collagen bundles’;
• dilated and tortuous ’linear blood vessels’ and ’coiled blood vessels’;
• ’bright dendritic structures’ within tumour islands; and
• ’bright round cells’ in the stroma.
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: no further details provided
Disease positive: 45 BCCs; disease negative: 9
Target condition (final diagnoses): BCC: 45; ’benign’ diagnoses: 9
Flow and timing Excluded participants: imaging with both TWP-RCM and HH-RCM was attempted in 92 lesions
from 73 participants; however, 38 (41%) of the lesions, mostly facial, were excluded as they were
only accessible to HH-RCM imaging
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included participants
and chosen study setting appro-
priate?
No
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Castro 2015 (Continued)
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
52Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Castro 2015 (Continued)
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Curchin 2011
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: January 2010 to May 2010
Country: Australia
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Curchin 2011 (Continued)
Patient characteristics and set-
ting
Inclusion criteria: people fromDermatology Department’s minor excision booking list; not further
described
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): number included: 42
Sample size (lesions): number included: 50
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests RCM: Vivascope 1500; RCM score (Pellacani 2007) and LM score for suspected LM of the face
(Guitera 2010)
Method of diagnosis: in-person diagnosis
Prior test data: dermoscopy “dermoscopic and RCM images were aligned over the top of each other
so that correlation between the two could be made.”
Diagnostic threshold: for melanoma - RCM score: ≥ 3; threshold for LM score for suspected LM
of the face was not described (Guitera 2010). Observer diagnosis for SCC/BCC; RCM features
listed
Diagnosis based on: single observer; (n = 1?)
Observer qualifications: NR
Experience in practice: not described
Experience with index test: low experience/novice users; analysis was performed by a novice to
RCM analysis after completing an RCM analysis course in Modena, Italy
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: no further details provided
Disease positive: 21; disease negative: 29
Target condition (final diagnoses): melanoma (invasive): 12; melanoma (in situ): 1; BCC: 9;
cSCC: 6 (included SK or AK, or both); ’benign’ diagnoses: 23
Flow and timing Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Curchin 2011 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Curchin 2011 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
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Farnetani 2015
Study characteristics
Patient sampling Study design: case series; series of cases consecutively and retrospectively selected by an expert
dermoscopist for a web based interobserver reliability study
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy (lesion image acquisition); observers were located in the USA (3), Europe (4),
Australia (1), and Israel (1)
Patient characteristics and set-
ting
Inclusion criteria: diagnostically equivocal lesions excised due to clinical or dermoscopic suspicion
of melanoma, where a specific clinical and dermoscopic diagnosis could not be rendered with
certainty. Lesions selected by an expert dermoscopist blinded to final diagnosis
Setting: secondary (general dermatology); all included RCM images were collected at the Depart-
ment of Dermatology of the University of Modena and ReggioEmilia (Modena, Italy)
Prior testing: clinical or dermatoscopic suspicion, or both
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: poor-quality index test image; ”No additional selection criteria were considered
in case selection such as the presence or lack of pigmentation, diameter, elevation, or other clinical
or dermoscopic attribute
Sample size (participants): number included: NR
Sample size (lesions): number included: 100
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests RCM: Vivascope 1500; no algorithm - evaluators completed a ’pattern description’ (presence/
absence of a number of RCM features)
Method of diagnosis: confocal images (remote); 3 RCM mosaic images presented per lesion
Prior test data: dermoscopy. “Each case for evaluation had a high-resolution dermoscopic image
obtained with a dermoscopic lens that was attached to a digital camera.” “No additional clinical
information (eg, age and melanoma or lesion history) was provided to evaluators.”
Diagnostic threshold: evaluators completed a ’pattern description’ (presence/absence of a number
of RCM features) and gave an overall diagnosis of malignant (melanoma or BCC) or benign
Diagnosis based on: single observer (results presented for each of 9 observers); consensus (≥ 5
of 9 evaluators); mean (across 9 observers and across 6 more experienced and 3 less experienced
observers) (n = 9)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with index test: low experience/novice users (3 with < 3 years’ RCM experience). High
experience/’expert’ users (6 with ≥ 3 years’ RCM experience)
Derivation aspect to study: in addition to pattern analysis described above, discriminant analysis
was used to identified RCM features independently associated with malignancy, melanoma, and
BCC. 3 of 6 discriminatory RCM features weremore frequently observed inmelanoma: the presence
of pagetoid cells, the presence of atypical cells at theDEJ, and irregular epidermal architecture; 3 of 6
discriminatory RCM features were more frequently observed in BCCs: basaloid cord-like structures,
presence of ulceration, and a specific DEJ pattern. Accuracy was not estimated for combinations of
these particular features
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: no further details provided
Disease positive: 35; disease negative: 65
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Farnetani 2015 (Continued)
Target condition (final diagnoses): melanoma (in situ and invasive, or NR): 20; BCC: 15; sebor-
rhoeic keratosis: 7; other: 55 melanocytic nevi, 3 AK
Flow and timing Excluded participants: excised lesions only included
Time interval to reference test: NR
Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low Unclear
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
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Farnetani 2015 (Continued)
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Farnetani 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Guitera 2012
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: NR
Country: Australia and Italy
Test set derived: randomly split into training and test sets
Patient characteristics and set-
ting
Inclusion criteria: consecutive participants presenting or found with suspicious lesions, including
all macules of the face and neck suspicious for LM, and which would be subjected to biopsy or
excision to rule out an epithelial tumour or anMM following conventional clinical and dermoscopy
diagnosis and with lesion location amenable to RCM; described as predominantly melanocytic or
suspicious for BCC
Setting: mixed, lesions recruited from Modena (general dermatology) and Sydney (skin cancer/
pigmented lesions clinic)
Prior testing: clinical or dermatoscopic suspicion, or both
Exclusion criteria: location/site of lesion keratotic, sole, and palm lesions were excluded
Sample size (participants): number eligible: 663
Sample size (lesions): number eligible: 710 / number included: 356 in test set, 253 melanocytic
Participant characteristics: median age (full sample): 53, IQR 39 to 66 (for full sample), range:
6-90; male: 354 (53.4%) (of full sample)
Lesion characteristics: NR
Index tests RCM: RCM score and Segura algorithm; also derived own independently significant features for
MM and BCC. Vivascope 1500
Method of diagnosis: confocal images (remote)
Prior test data: lesion site or participant age only, or both: “RCM features were described by two
expert observers (GP and PG), blinded from any clinical information, dermoscopy, and clinical
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Guitera 2012 (Continued)
aspects, but not for the location and age of the patient.”
Diagnostic threshold: 2 established algorithms assessed: Pellacani scoring system for melanoma
(Pellacani 2007), score > 3; and Segura 2-step algorithm (Segura 2009), score of 0; own new 2-
step model identified 7 independently significant features for MM (assume presence of any one
indicated T+):
• cerebriform nests,
• atypical cobblestone pattern with small nucleated cells in the epidermis,
• marked cytological atypia,
• pagetoid cells,
• disarranged epidermal layer with no honeycomb,
• large inter-papillae spaces filled with honeycomb,
• dense nest.
8 independently significant features for BCC:
• polarised in the honeycomb,
• linear telangiectasia-like horizontal vessels,
• basaloid cord or nodule,
• epidermal shadow,
• convoluted glomerular-like vessels,
• non-visible papillae,
• cerebriform nests,
• disarray of the epidermal layer.
Derivation aspect to study: lesion characteristics assessed a series of 48 features, corresponding
to previous observations (Pellacani 2007; Guitera 2009), and new descriptors were considered at 3
different depth levels. Descriptions and definitions provided
Selection of characteristics indicative of skin cancer by multivariate discriminant analysis performed
on the training set
Diagnosis based on: single observer (n = 2)
Observer qualifications: dermatologist
Experience in practice: high experience or ’expert’
Experience with index test: high experience/’expert’ users
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: not further described; full sample
Disease positive: 335/disease negative: 375
Target condition (final diagnoses): test set only; melanoma (in situ and invasive, or NR): 105;
BCC: 52; cSCC: 9 benign nevus 132; Spitz nevus 16; AK 8; 31 benign macule of the face; and 3
dermatofibroma
Flow and timing No exclusions
Imaged prior to biopsy
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Guitera 2012 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
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Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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Guitera 2012 (Continued)
1 month or less?
Low
Incel 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective (assumed); “Written consent was obtained from all participants before
enrolment.”
Period of data collection: NR
Country: Turkey
Patient characteristics and set-
ting
Inclusion criteria:peoplewith non-pigmented suspected tumoral lesions or proliferative skin lesions
and with a vascular structure on dermoscopic examination
Setting: secondary (not further described) Istanbul Training and Research Hospital
Prior testing: clinical or dermatoscopic suspicion, or both - all participants underwent clinical
evaluations “following guidelines of the visual inspection and diagnosis of nonpigmented skin
tumor;” those with a vascular structure on dermoscopic examination underwent RCM
Setting for prior testing: secondary (general dermatology); specialist unit (skin cancer/pigmented
lesions clinic)
Exclusion criteria: prominent hyperkeratosis; history of significant other skin disease, kidney, liver,
heart disease, surgery, or invasive procedure on the localisation of tumour in the last 6 months,
sunbathing or indoor tanning in the last 3months, and people receiving therapy that has angiogenic
effects such as systemic/topical steroids
Sample size (participants): number included: 114
Sample size (lesions): number included: 122
Participant characteristics: median age 61 years, range 18-87 years; male: 57%
Lesion characteristics: site - head and neck: 76.2%; extremities: 10.2%; back, abdomen, and chest:
13.6%
Index tests RCM: characteristics from previous studies selected to assist correct diagnosis of different lesion
types; also assessed vascularity of lesions using RCM but this did not inform diagnosis. Vivascope
3000
Method of diagnosis: unclear; images of first 60 lesions subjected to blinded evaluation by 2
observers to identify vascular morphology; unclear whether overall diagnoses reported were based
on images or in-person assessments
Prior test data: unclear
Diagnostic threshold: characteristics listed for BCC included: dark silhouettes in dermis, bright tu-
mour islands at DEJ and in the dermis; cleft-like dark areas; dendritic cells, bright rond cells, canalic-
ular vessels. Characteristics listed for SCC included: refractile squam/crust in stratum corneum
and nucleated cells with dark centre (parakeratotic) cells; atypical honeycomb pattern, disarranged
pattern at stratum granulosum layer; large, round, nucleated cells at the granular layer (dyskeratotic
cells); dendritic cells at the granular layer and small edged papillae at DEJ; dendritic cells (referenced
to Ahlgrimm-Siess 2010; Ahlgrimm-Siess 2011; Eichert 2010;Malvehy 2012; Röwert-Huber 2007)
Derivation aspect to study: study assessed vascularity of lesions with RCM but diagnoses of each
lesion type reportedly based on above characteristics
Diagnosis based on: NR
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Incel 2015 (Continued)
Observer qualifications: NR
Experience in practice: NR
Experience with index test: NR
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: clinically, dermoscopically, and confocally suspectedmalignant lesions, recurrent, and ther-
apy resistant lesions were excised; benign appearing but suspected lesions were punch biopsied. For-
malin fixed paraffin embedded tissue sections were stained with haematoxylin-eosin. Histopatho-
logical examination was conventionally operated by light microscopy
Target condition (final diagnoses): BCC: 56; cSCC: 9; keratoacanthoma 3; SK 11; AK 8; Bowen’s
disease 7; and 24 other non-pigmented tumours that included sebaceous hyperplasia 4, eccrine
poroma 4, pyogenic granuloma 3, amelanotic melanoma 2, sebaceous adenoma 2, trichilemmoma
2, warty dyskeratoma 1, pilomatrixoma 1, kaposi sarcoma 1, fibrohistiocytic tumour 1, eccrine
spiradenoma 1, and eccrine porocarcinoma 1
Flow and timing Index to reference interval: appears consecutive “Biopsy was taken for routine histology from selected
patients, and was examined with RCM.”
No exclusions reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Reflectance confocal microscopy
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Longo 2013
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically nodular lesions (defined as cutaneous palpable/superficial seated lesions
and not subcutaneous ones) that underwent excision
Setting: secondary (general dermatology); specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: selected for excision (no further detail)
Setting for prior testing: secondary (general dermatology); specialist unit (skin cancer/pigmented
lesions clinic)
Exclusion criteria: none reported (not evaluable and non-specific RCM results excluded; see below)
Sample size (participants): number included: 140
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Sample size (lesions): number included: 140
Participant characteristics: mean age 50 years (SD 19.7). Male: 64; 45.7%
Lesion characteristics: all clinically nodular; site - ’most’ on the trunk; dermatofibroma mainly
located on extremities. Mean thickness 2.16 mm (SD 82); 23 ’pure’ nodular melanomas
Index tests RCM: model NR; likely Vivascope 1500. No algorithm - reports observer diagnosis and indepen-
dently significant features
Method of diagnosis: confocal images (remote)
Prior test data: no further information used; blinded to dermoscopic image
Diagnostic threshold: a diagnosis was formulated based on ’RCM pattern analysis’ (Longo 2011;
Pellacani 2007; and several others cited)
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist
Experience in practice: high experience or ’expert’; 5 years’ experience in RCM and, therefore,
presumably in practice
Experience with index test: high experience/’expert’ users; 5 years’ experience in RCM
Derivation aspect to study: main study data included relate to observer’s interpretation of RCM
characteristics and diagnostic classification. Univariate and then multivariate discriminant analysis
was also performed to identify independently significant RCM criteria (total of 36 assessed) for
NM+Mets (nodular melanoma +metastasis) vs all other diagnoses, BCC vs all other diagnoses, SCC
vs all other diagnoses. However, the data presented relate to only 130 lesions, and the melanoma
metastases cannot be separated from the nodular melanoma, therefore melanoma data not included.
Characteristics selected for nodular melanoma or melanoma mets were: widespread pagetoid distri-
bution; many atypical cells; and cerebriform nests. Characteristics selected for BCC were: tumour
islands; cauliflower architecture; bright filaments within the tumour islands; and presence of bright
collagen. Not clearly reported for SCC
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: no further details provided
Disease positive: 66; disease negative: 57
Target condition (final diagnoses): melanoma (invasive): 23 nodular; BCC: 28; cSCC: 6; other
malignant: 9 melanoma metastases; SK: 14; benign naevus: 32 (14 compound, 8 intradermal, 3
blue naevi, 7 Spitz naevi); other: 5 vascular and 6 other benign lesions
Flow and timing Excluded participants: 8 not evaluable and 3 ’non-specific’ RCM results reported (appear to be
excluded from derivation of independently significant characteristics)
Not evaluable: lesions where all the 3 levels (epidermis, DEJ, and upper dermis) were not explorable
for any reason that hampered the collection of quality images or the exploration of DEJ/superficial
dermis. Non-specific: lesions where a diagnosis could not be formulated, despite the possibility of
exploring all 3 levels, because of the impossibility of recognising diagnostic features with enough
confidence
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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1 month or less?
Unclear
Nori 2004
Study characteristics
Patient sampling Study design: case control; appears to be case-control type design sampling BCC and non-BCC
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 2 years - date range not specified
Country: USA and Spain
Patient characteristics and set-
ting
Inclusion criteria: biopsy-confirmed BCC and convenience sample of non-BCC with ’range of
commondiagnoses’ (only 7of the 69non-BCChadBCCon the list of possible differential diagnoses)
; of these 105 images were selected for clinical assessment based on superior clinical image quality
Setting: secondary (general dermatology) Division of Dermatology, Loma Linda Uni Med School;
Dermatology Service, Madrid, Spain; Private care (Dermatology and Dermatologic surgery private
practice); Wellmann Laboratories of Photomedicine, Massachusetts General Hospital
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): number included: 145
Sample size (lesions): number included: 152; 105 in VI analysis
Participant characteristics: male: 98; 64%
Lesion characteristics: lesion site: face/ears: 35%; trunk: 13%; limbs: extremities 45%; back 7%
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used
Diagnostic threshold:NR. Lesions assigned to: high probability (BCC until confirmed otherwise)
, medium probability (would biopsy to rule out BCC), and low probability (no biopsy needed)
Diagnosis based on: single observer (n = 2)
Observer qualifications: dermatologist
Experience in practice: not described
Experience with index test: not described
RCM:Vivascope 1000 (plus prototype device built inWellmanLaboratories (n =20)).No algorithm;
selected characteristics assessed (referenced to Gonzalez 2002)
Method of diagnosis: confocal images (remote)
Prior test data:no further information used; images from all 152 lesions was retrospectively analysed
in a blinded fashion
Diagnostic threshold: ≥ 2, 3, 4 or 5 present of 5 features selected based on prior study by same
authors (elongated monomorphic basaloid nuclei; polarisation of these nuclei along the same axis
of orientation; prominent inflammatory infiltrate; increased dermal vasculature; pleomorphism of
the overlying epidermis indicative of actinic changes)
Diagnosis based on: single observer (n = 1)
Observer qualifications: ’novice confocal reviewer’ reviewed all images
Experience in practice: not described
Experience with index test: low experience/novice users; novice confocal reviewer
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Other detail: the images produced by Vivascope 1000 and prototype device reportedly similar, with
no measurable differences between them
Derivation aspect to study: the 5 criteria were chosen as they were “easily and unambiguously
detected by non dermatopathologists and our novice reviewer so that the applicability of our results
would be useful to the dermatology community as a whole.”
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis plus other
Details: 15 lesions were not biopsied (e.g. lesions like SK) because the clinical diagnosis was con-
sidered diagnostic
Histology: disease positive: 83; disease negative: 54
Expert opinion: disease positive: 0; disease negative: 15
Target condition (final diagnoses): BCC: 83; 58 in VI analysis; cSCC: 4; ’benign’ diagnoses: 65
Flow and timing -
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included participants
and chosen study setting appro-
priate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
73Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nori 2004 (Continued)
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Unclear
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Pellacani 2014a (cons)
Study characteristics
Patient sampling Study design: case series (consultation group documented here)
Data collection: prospective
Period of data collection: January 2010 to December 2010
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: people requesting amole check or with suspicion of melanomawho were referred
to PLC and who were then found to have atypical lesions on dermoscopy. Those in whom diagnosis
could not be determined on dermoscopy were referred for an ’outcome decision’ (consultation
group). Participants were referred on the basis of both urgent access (melanoma suspected in a single
lesion by GP or other dermatologist) and scheduled access (referred for dermoscopy and total body
examination)
Setting: specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: dermatoscopic suspicion in all cases. All participants underwent dermoscopy in the
PLC; those with dermoscopically atypical lesions were referred for RCM, either to document a
lesion already selected for excision (documentation group, reported in Pellacani 2014b (doc)) or for
an ’outcome decision’ (consultation group), i.e. diagnosis could not be determined on dermoscopy
Setting for prior testing: specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: clinically or dermatoscopically clear-cut epithelial tumours, or both, were not
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enrolled; poor-quality index test image. In 9 cases, RCM could not be performed (5 RCM docu-
mentation and 4 RCM consultation) due to the presence of artefacts, hyperkeratosis, or ulcerations,
impeding imaging
Sample size (participants): number eligible: 1005 examined with dermoscopy; number included:
252 referred for RCM consultation
Sample size (lesions): number eligible: NR; number included: 308 for RCM documentation
Participant characteristics: median age 41.7 years (IQR 31.9 to 52.1 years); for all 1005 referred
participants: 443 male (44%); consultation group only: history of melanoma/skin cancer 23 (7%)
; family history of melanoma 30 (10%). Fitzpatrick phototype I to II: 150 (49%); Type III to IV
116 (38%)
Lesion characteristics: lesion site (full sample) head/neck: 9%; trunk: 59%; upper limbs/shoulder:
12%; lower limbs/hip: 20%
Index tests RCM: RCM score. Vivascope 1500
Method of diagnosis: in person
Prior test data: participants were “referred to confocal unit;” confocal reader was blinded to the
participant pathway and aware that lesions were dermoscopically atypical for ’RCM documentation’
or for ’RCM consultation.’
Diagnostic threshold: NR, Pellacani 2005 cited
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist (assumed; participants were “referred to confocal unit”)
Experience in practice: not described
Experience with index test: not described but ’confocal unit’ described
Other detail: dermatoscopy examinations were conducted using the Dermlite HR (3Gen LLC, San
JuanCapistrano, CA,USA). Lesions that were scheduled for digital monitoringwere also acquired by
means of FotoFinder (TeachScreen GmbH, Bad Birnbach, Germany) using 20-fold magnification
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis plus FU and cancer registry FU
Histology (not further described): 81 (consultation group); overall dataset - 292 excised (see
Pellacani 2014b (doc))
Clinical FU:227. 28ofwhichwere subsequently excised because of observed dermatoscopic changes
(all benign). Most non-excised lesions (178/199 (89.4%)) were followed up for 1 year; the others
were lost at the 1-year FU
Cancer registry FU: those lost to clinical FU were checked on the tumour registry; no melanomas
were diagnosed in participants scheduled for FU after baseline examinations
Target condition (final diagnoses): melanoma (invasive): 13; melanoma (in situ): 9; BCC: 19;
1 melanoma metastasis; Clark naevus 71; Spitz nevus 5; solar lentigo, SK or lichen planus-like
keratosis 0; other benign 207 (8 with histological diagnosis (25 Clark naevi, 2 Spitz naevi and 1
benign non-melanocytic lesion) and 199 benign on FU)
Flow and timing Excluded participants: 9 excluded due to RCM failure
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included participants
and chosen study setting appro-
priate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
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Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
Yes
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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1 month or less?
High
Pellacani 2014b (doc)
Study characteristics
Patient sampling Study design: case series (documentation group described here)
Data collection: prospective
Period of data collection: January 2010 to December 2010
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: people requesting a mole check or with suspicion of melanoma who were
referred to PLC and who were then found to have atypical lesions on dermoscopy. Those in whom
excisionwas required ondermoscopywere referred forRCMdocumentation (documentation group)
. Participants were referred on the basis of both urgent access (melanoma suspected in a single
lesion by GP or other dermatologist) and scheduled access (referred for dermoscopy and total body
examination)
Setting: specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: dermatoscopic suspicion in all cases. All participants underwent dermoscopy in the
PLC; those with dermoscopically atypical lesions were referred for RCM, either to document a lesion
already selected for excision (documentation group, as reported here) or for an ’outcome decision’
(consultation group, reported in Pellacani 2014a (cons)), i.e. diagnosis could not be determined on
dermoscopy.
Setting for prior testing: specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: clinically or dermatoscopically clear-cut epithelial tumours, or both, were not
enrolled; poor-quality index test image. In 9 cases, RCM could not be performed (5 RCM docu-
mentation and 4 RCM consultation) due to the presence of artefacts, hyperkeratosis, or ulcerations,
impeding imaging
Sample size (participants): number eligible: 1005 examined with dermoscopy; number included:
171 referred for RCM documentation
Sample size (lesions): number eligible: NR; number included: 183 for RCM documentation
Participant characteristics: median age 41.2 years (IQR 35 to 63 years); for all 1005 referred
participants: 443 male (44%); history of melanoma/skin cancer 8 (5%); family history of melanoma
13 (8%). Fitzpatrick phototype I to II: 99 (58%); Type III to IV 72 (42%)
Lesion characteristics: lesion site (full sample) head/neck: 9%; trunk: 59%; upper limbs/shoulder:
12%; lower limbs/hip: 20%
Index tests RCM: RCM score. Vivascope 1500
Method of diagnosis: in person
Prior test data: participants were “referred to confocal unit;” confocal reader was blinded to the
participant pathway and aware that lesions were dermoscopically atypical for ’RCM documentation’
or for ’RCM consultation.’
Diagnostic threshold: NR, Pellacani 2005 cited
Diagnosis based on: single observer (n = 1)
Observer qualifications: dermatologist (assumed; participants were “referred to confocal unit”)
Experience in practice: not described
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Experience with index test: not described but ’confocal unit’ described
Other detail: dermatoscopy examinations were conducted using the Dermlite HR (3Gen LLC, San
JuanCapistrano, CA,USA). Lesions that were scheduled for digital monitoringwere also acquired by
means of FotoFinder (TeachScreen GmbH, Bad Birnbach, Germany) using 20-fold magnification
Target condition and reference
standard(s)
Type of reference standard:histology alone for documentation group; 227 from consultation group
were referred for FU (see Pellacani 2014a (cons))
Target condition (final diagnoses): melanoma (invasive): 13; melanoma (in situ): 9; BCC: 19;
1 melanoma metastasis; Clark naevus 121; Spitz nevus 8; solar lentigo, SK or lichen planus-like
keratosis 7; other benign 5 (haemosiderotic dermatofibroma, xanthogranuloma, viral wart, and 2
non-specific inflammatory dermatoses)
Flow and timing Excluded participants: 9 due to RCM failure
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included participants
and chosen study setting appro-
priate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
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Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
Yes
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Rao 2013
Study characteristics
Patient sampling Study design: case series
Data collection: NR. Appeared to be prospective but not explicitly stated
Period of data collection: June 2010 to September 2011
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: all lesions removed for cosmetic or medical reasons that were imaged using a
confocal scanning microscope
Setting: secondary (general dermatology) based on author institutions
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: 340; number included: 334
Participant characteristics: none reported
Lesion characteristics: none reported
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Index tests RCM: Vivascope 1500. No algorithm; overall diagnosis
Method of diagnosis: in-person diagnosis USA (reader 1; less experienced)
Confocal images (remote) Modena, Italy; reader 2 (more experienced)
Prior test data: for image based, “diagnosis was based on the dermoscopic image and confocal
microscopy evaluation before excision.”
Diagnostic threshold: NR; observers gave diagnosis and excise decision (no further details)
Diagnosis based on: single observer (n = 2)
Observer qualifications: NR; presume dermatologists
Experience in practice: not described
Experience with index test: low experience/novice users reader 1 (USA) had 1 year of experience
at the beginning of the study; High experience/’expert’ users reader 2 (Italy) had over 9 years of
experience with RCM
Other detail: images were sent via Vivanet (CaliberID, Rochester, NY, USA), a Health Insurance
Portability and Accountability Act compliant server
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: no further details provided
Disease positive: 78; disease negative: 256
Target condition (final diagnoses): melanoma (invasive): 8; melanoma (in situ); 1; BCC: 27;
cSCC: 42; Benign nevi 176; SK 22; AK 24; other 23
Flow and timing Excluded participants: 6 described as excluded because of insufficient information. Furthermore,
318/334 reported for reader 1 and 323/334 reported for reader 2
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included participants
and chosen study setting appro-
priate?
Unclear
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Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Rao 2013 (Continued)
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Witkowski 2016
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January 2009-2011
Country: Italy
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Witkowski 2016 (Continued)
Patient characteristics and set-
ting
Inclusion criteria: consecutive clinically equivocal ’pink’ cutaneous lesions with absent pigmen-
tation or containing < 10% pigment and absence of pigment network. All lesions were excised at
first visit or FU videodermoscopy control visit and had available digital dermoscopy images and a
complete standard set of RCM images, with histopathology reports
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: unequivocal appearance/diagnosis benign diagnosis made with high confidence;
lack of histological report as a result of the lesion not being excised
Sample size (participants): NR
Sample size (lesions): number eligible: 3869 consecutive cases were reviewed; number included:
260
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Dermoscopy: no algorithm
Method of diagnosis: dermoscopic images
Prior test data: no further information used
Diagnostic threshold: not described in detail, but accuracy presented for 2 diagnostic decisions:
correct diagnosis (of BCC, MM, and SCC) and correct management decision (excise or not)
Diagnosis based on: single observer (n = 2; 1 reader evaluated only dermoscopic images while the
second reader evaluated RCM images)
Observer qualifications: NR; likely dermatologist
Experience in practice: not described
Experience with index test: not described
RCM: Vivascope 1500; no algorithm - overall diagnosis
Method of diagnosis: confocal images (remote)
Prior test data: no further information used “The first reader (JL) evaluated only dermoscopic
images while the second reader (AW) evaluated RCM images.”
Diagnostic threshold: NR. Not described in detail, but accuracy presented for 2 diagnostic deci-
sions: correct diagnosis (of BCC, MM, and SCC) and correct management decision (excise or not)
Diagnosis based on: single observer (n = 1)
Observers: as described above
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: no further details provided
Disease positive: 140; disease negative: 120
Target condition (final diagnoses):melanoma (in situ and invasive, or NR): 12; BCC: 114; cSCC:
13; 1 syringoid eccrine carcinoma; SK plus other: 25 (solar lentigo/SK/lichen planus-like keratosis/
AK); 47 nevi; 6 Spitz nevi; 18 dermatofibromas, 4 vascular lesions, and 20 other type benign lesions
(1 clear cell acanthoma, 1 discoid lupus, 10 inflammatory lesions, 1 perivascular hyperplasia, 4
granulomatous hyperacanathosis reactions, 1 papulous fibrosis, 1 eccrine poroma, and 1 eczematous
lesion)
Flow and timing Excluded participants: around 357 cases excluded due to the lack of a histopathology report, as a
result of the lesion not being excised, or a benign diagnosis was made with high confidence
Time interval to reference test: NR
Time interval between index test(s): NR
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Witkowski 2016 (Continued)
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low Unclear
DOMAIN 2: Index Test Reflectance confocal microscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Witkowski 2016 (Continued)
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Witkowski 2016 (Continued)
Was the minimum clinical fol-
low-up after application of in-
dex test(s) adequate?
If more than one algorithm
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
AK: actinic keratosis; BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; DEJ: dermoepidermal junction; FU:
follow-up; GP: general practitioner; HH-RCM: hand-held reflectance confocal microscopy; IQR: interquartile range; LM: lentigo
maligna; MM: malignant melanoma; N/A: not applicable/available; NR: not reported; PLC: pigmented lesion clinic; RCM: re-
flectance confocal microscopy; SCC: squamous cell carcinoma; SD: standard deviation; SK: seborrhoeic keratosis; TWP-RCM:
traditional wide-probe reflectance confocal microscopy; VI: visual inspection.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agero 2006 Excluded on sample size; only 5 lesions
Ahlgrimm-Siess 2010 Excluded on study population; BCC only
Excluded on sample size; only 2 cases
Ahlgrimm-Siess 2011 Excluded on study population; SCC only
Excluded on sample size; only 2 cases
Alarcon 2014 Excluded on sample size; target condition (eligible for melanoma review only)
Amjadi 2011 Excluded on target population; included only BCC (82)/SCC (48) and 8 AK/SK lesions; primary aim
appeared to be to differentiate BCC and SCC despite describing inclusion of clinically difficult to
diagnose non-pigmented lesions
Excluded on derivation study
Bassoli 2012 Excluded on target condition; aimed to identify criteria for specific diagnosis of LPLK using in vivo
RCM
Benati 2015 Excluded on individual lesion characteristics
Braga 2009 Excluded on sample size; case reports
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(Continued)
Carrera 2015 Excluded as not a primary study
de Carvalho 2015 Excluded on individual lesion characteristics
Excluded on 2×2 data
de Carvalho 2016 Excluded on target condition
Excluded on sample size
Edwards 2016 Excluded as not a primary study; systematic review
Eichert 2010 Excludes on individual lesion characteristics; looked at accuracy of previously identified RCM features
for melanoma, BCC and SCC in a cohort of 100 lesions but did not give accuracy for overall diagnosis
of each group
Ferrari 2015 Excluded on target condition (eligible for melanoma review only)
Figueroa-Silva 2016 Excluded on target condition (eligible for melanoma review only)
Gareau 2009 Excluded on study population; only BCC cases
Gerger 2005 Excluded on reference standard; only 1/3 of disease negative group had adequate reference test
Excluded; duplicate or related publication; data reported as training set in Koller 2011 (#860)
Gerger 2006 Excluded on reference standard
Only 30/120 benign were excised (30/90 benign nevi and 0/30 SK)
Gerger 2008 Excluded on reference standard
All MMs were excised plus 14/50 benign; remainder diagnosed on clinical/dermoscopic criteria
Giambrone 2015 Excluded on target condition
Excluded but contacted authors
they do not give information on the target condition other than describing malignant and benign
cutaneous lesions. Contacted 8 May 2017
Gill 2014 Excluded as derivation study; looking for correlation with histological features
Excluded on 2×2 data; looked at correlation between RCM features and histological features; not test
accuracy
Excluded duplicate or related publication; same lesions reportedly included in Pellacani 2012
Gonzalez 2002 Excluded on population included only BCC
Gonzalez 2013 Excluded not a primary study
Guida 2015 Excluded not a primary study; systematic review
Guitera 2009 Excluded on target condition (eligible for melanoma review only)
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(Continued)
Guitera 2010 Excluded on target condition; only looking at LM and not LMM
Guitera 2013 Excluded on study population; LM and LMM only
Excluded on target condition; data only available for LM
Excluded on 2×2 data
Haenssle 2006 Excluded on index test; surveillance study estimating accuracy of different approaches to follow-up
Hennessy 2010 Excluded on 2×2 data
Hofmann-Wellenhof 2008 Excluded on reference standard; included 70 melanocytic lesions; 20 MM (all histologically verified);
70 benign naevi (28% histologically verified, and the rest diagnosed with dermoscopy only)
Hoogedoorn 2014 Excluded; conference abstract
Hoogedoorn 2015 Excluded on sample size
Humphrey 2006 Excluded on study population
Excluded as derivation study; assessed lesion vascularity
Kadouch 2015a Systematic review
Kadouch 2015b Excluded not a primary study; clinical trial protocol
Koller 2011 Excluded on target condition (eligible for melanoma review only)
Kose 2014 Excluded not a test accuracy study
Excluded on 2×2 data
Langley 2001 Excluded on 2×2
Excluded, contacted authors for RCM 2×2 data; could only get 2×2 for clinical diagnosis
Langley 2006 Excluded on sample size
Langley 2007 Excluded on target condition (eligible for melanoma review only)
Losi 2014 Excluded if individual lesion characteristics
Excluded on 2×2 data
Lovatto 2015 Excluded on target condition (eligible for melanoma review only)
Maier 2013 Excluded on study population; all study participants had final diagnosis of melanoma
Malvehy 2012 Excluded not a primary study; review paper
Menge 2016 Excluded on target population; included participants with primary possible recurrent and or previously
treated lesions and did not disaggregate results. Also included multiple lesions per participant (63 ’sites’
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(Continued)
from 17 participants; unclear how many of the 39 LM positive on histology had melanoma)
Miller 2011 Excluded on target condition
Excluded on 2×2 data; not an accuracy study
Nobre Moura 2011 Excluded on sample size; case report
Pellacani 2005 Excluded if derivation study; used leave 1 out
Pellacani 2007 Excluded on target condition (eligible for melanoma review only)
Pellacani 2008 Excluded on 2×2 data; no accuracy data provided in the study, looked at correlation of RCM features
to dermoscopy and histology
Pellacani 2009 Excluded on 2×2 data; study tested concordance of terminology used in RCM; not accuracy
Pellacani 2012 Excluded on target condition (eligible for melanoma review only)
Peppelman 2013 Excluded on study population; only present data for subtypes of BCC
Excluded on 2×2 data; did not give accuracy data
Peppelman 2015 Excluded if derivation study
Excluded on 2×2 data; no data for overall accuracy
Peppelman 2016 Excluded as not a primary study; RCT protocol
Puig 2012 Excluded on sample size; case report
Pupelli 2013 Excluded on target condition (eligible for melanoma review only)
Reggiani 2015 Excluded not a primary study; systematic review
Rishpon 2009 Excluded on sample size; only 3 invasive SCC
Excluded if derivation study RCM characteristics for SCC
Röwert-Huber 2007 Excluded not a primary study; review paper
Salerni 2011 Excluded on sample size; < 5 cases
Scope 2009 Excluded on sample size
Scope 2014 Excluded as not a primary study; editorial paper
Segura 2009 Excluded on target condition (eligible for melanoma review only)
Soyer 2013 Excluded as not a primary study; comment on a primary study (Longo 2013)
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(Continued)
Stanganelli 2015 Excluded on target condition (eligible for melanoma review only)
Steiner 1992 Excluded on sample size; only 2 melanomas
Stephens 2013 Excluded on sample size
Stevenson 2013 Excluded not a primary study; systematic review of RCM
Tannous 2009 Excluded on sample size; only 2 malignant melanomas
Willard 2011 Excluded on sample size; case study
Xiong 2016 Excluded as not a primary study; systematic review of RCM
Yelamos 2016 Excluded as not a primary study
AK: actinic keratosis; BCC: basal cell carcinoma; LM: lentigo maligna; LMM: lentigo maligna melanoma; LPLK: lichen planus-like
keratosis; RCM: reflectance confocal microscopy; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SK: solar
keratosis. See also Appendix 2.
Characteristics of studies awaiting classification [ordered by study ID]
Borsari 2016
Study characteristics
Patient sampling Not yet assessed
Patient characteristics and set-
ting
Not yet assessed
Index tests Not yet assessed
Target condition and reference
standard(s)
Not yet assessed
Flow and timing Not yet assessed
Comparative Not yet assessed
Notes Published October 2016; after search dates
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Guitera 2016
Study characteristics
Patient sampling Not yet assessed
Patient characteristics and set-
ting
Not yet assessed
Index tests Not yet assessed
Target condition and reference
standard(s)
Not yet assessed
Flow and timing Not yet assessed
Comparative Not yet assessed
Notes Published October 2016; after search dates
Jain 2017
Study characteristics
Patient sampling Not yet assessed
Patient characteristics and set-
ting
Not yet assessed
Index tests Not yet assessed
Target condition and reference
standard(s)
Not yet assessed
Flow and timing Not yet assessed
Comparative Not yet assessed
Notes Published March 2017; conference abstract only
Ludzik 2016
Study characteristics
Patient sampling Not yet assessed
Patient characteristics and set-
ting
Not yet assessed
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Ludzik 2016 (Continued)
Index tests Not yet assessed
Target condition and reference
standard(s)
Not yet assessed
Flow and timing Not yet assessed
Comparative Not yet assessed
Notes Published September 2016; after search dates
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Basal cell carcinoma (BCC) -
any suspicious lesion
4 912
2 BCC - equivocal lesions 3 668
3 BCC - other lesion populations 4 457
4 BCC - reflectance confocal
microscopy (RCM) - other -
Vivascope 3000
1 54
5 BCC - dermoscopy - equivocal
lesions
1 260
6 BCC - visual inspection - other
lesion populations
1 105
7 Squamous cell carcinoma (SCC)
- RCM - all comer
1 323
8 SCC - RCM - equivocal 1 260
9 SCC - RCM - other 2 251
10 SCC - dermoscopy - equivocal 1 260
11 All keratinocyte skin cancer
(KER) - RCM - all comer
2 373
12 KER - RCM - equivocal 2 360
13 KER - RCM - other 1 129
14 KER - dermoscopy - equivocal 1 260
15 Malignant melanoma
(MM)2 - RCM - equivocal
(non-pigmented) not in
melanoma review
1 260
16 BCC - RCM score at ≥ 3 - in
person
1 50
17 BCC - RCM score at NR
(likely ≥ 3) - in person
2 491
18 BCC - Guitera 2-step algorithm
(significant chars for BCC) -
image based
1 356
19 BCC - no algorithm (significant
characteristics) - in person
1 54
20 BCC - no algorithm (significant
characteristics) - image based
1 130
21 BCC - no algorithm (selected
characteristics) - in person
1 122
22 BCC - no algorithm (selected
characteristics) - image based
1 152
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23 BCC - no algorithm (observer
diagnosis) - in person
1 318
24 BCC - no algorithm (observer
diagnosis) - image based
4 812
25 BCC - hand-held RCM -
no algorithm (significant
characteristics)
1 54
28 SCC - no algorithm (selected
characteristics) in person
1 122
29 SCC - no algorithm (observer
diagnosis) - in person
1 318
30 SCC - no algorithm (observer
diagnosis) - image based
3 712
33 KER - RCM at ≥ 3 - in person 1 50
36 KER - no algorithm (observer
diagnosis) - in person
1 318
37 KER - no algorithm (observer
diagnosis) - image based
4 812
38 KER - no algorithm (excise
decision) - in person
1 318
39 KER - no algorithm (excise
decision) - image based
2 583
40 BCC - by observer - high - in
person
3 545
41 BCC - by observer - high -
image based
4 908
42 BCC - by observer - low - in
person
2 368
43 BCC - by observer - low -
image based
2 252
44 BCC - by observer - NR - in
person
1 122
45 BCC - by observer - NR -
image based
1 260
47 SCC - by observer - low - in
person
1 318
48 SCC - by observer - NR - in
person
1 122
49 SCC - by observer - high -
image based
2 452
50 SCC - by observer - NR -
image based
1 260
52 KER - by observer - low - in
person
2 368
53 KER - by observer - high -
image based
3 552
54 KER - by observer - low - image
based
1 100
55 KER - by observer - NR -
image based
1 260
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Test 1. Basal cell carcinoma (BCC) - any suspicious lesion.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 1 Basal cell carcinoma (BCC) any suspicious lesion
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Curchin 2011 6 0 3 41 0.67 [ 0.30, 0.93 ] 1.00 [ 0.91, 1.00 ]
Guitera 2012 34 16 18 288 0.65 [ 0.51, 0.78 ] 0.95 [ 0.92, 0.97 ]
Pellacani 2014b (doc) 19 91 0 73 1.00 [ 0.82, 1.00 ] 0.45 [ 0.37, 0.52 ]
Rao 2013 14 7 13 289 0.52 [ 0.32, 0.71 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. BCC - equivocal lesions.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 2 BCC equivocal lesions
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 14 20 1 65 0.93 [ 0.68, 1.00 ] 0.76 [ 0.66, 0.85 ]
Pellacani 2014a (cons) 19 62 0 227 1.00 [ 0.82, 1.00 ] 0.79 [ 0.73, 0.83 ]
Witkowski 2016 97 9 17 137 0.85 [ 0.77, 0.91 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. BCC - other lesion populations.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 3 BCC other lesion populations
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Castro 2015 45 2 0 7 1.00 [ 0.92, 1.00 ] 0.78 [ 0.40, 0.97 ]
Incel 2015 51 0 5 66 0.91 [ 0.80, 0.97 ] 1.00 [ 0.95, 1.00 ]
Longo 2013 25 3 0 101 1.00 [ 0.86, 1.00 ] 0.97 [ 0.92, 0.99 ]
Nori 2004 78 15 5 54 0.94 [ 0.86, 0.98 ] 0.78 [ 0.67, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. BCC - reflectance confocal microscopy (RCM) - other - Vivascope 3000.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 4 BCC reflectance confocal microscopy (RCM) other Vivascope 3000
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Castro 2015 42 2 3 7 0.93 [ 0.82, 0.99 ] 0.78 [ 0.40, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. BCC - dermoscopy - equivocal lesions.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 5 BCC dermoscopy equivocal lesions
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 97 11 17 135 0.85 [ 0.77, 0.91 ] 0.92 [ 0.87, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. BCC - visual inspection - other lesion populations.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 6 BCC visual inspection other lesion populations
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nori 2004 28 18 30 29 0.48 [ 0.35, 0.62 ] 0.62 [ 0.46, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. Squamous cell carcinoma (SCC) - RCM - all comer.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 7 Squamous cell carcinoma (SCC) RCM all comer
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rao 2013 31 23 11 258 0.74 [ 0.58, 0.86 ] 0.92 [ 0.88, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. SCC - RCM - equivocal.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 8 SCC RCM equivocal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 10 4 3 243 0.77 [ 0.46, 0.95 ] 0.98 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. SCC - RCM - other.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 9 SCC RCM other
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Incel 2015 9 4 2 107 0.82 [ 0.48, 0.98 ] 0.96 [ 0.91, 0.99 ]
Longo 2013 5 0 0 124 1.00 [ 0.48, 1.00 ] 1.00 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. SCC - dermoscopy - equivocal.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 10 SCC dermoscopy equivocal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 10 3 3 244 0.77 [ 0.46, 0.95 ] 0.99 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. All keratinocyte skin cancer (KER) - RCM - all comer.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 11 All keratinocyte skin cancer (KER) RCM all comer
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Curchin 2011 19 3 3 25 0.86 [ 0.65, 0.97 ] 0.89 [ 0.72, 0.98 ]
Rao 2013 66 34 12 211 0.85 [ 0.75, 0.92 ] 0.86 [ 0.81, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 12. KER - RCM - equivocal.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 12 KER RCM equivocal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 30 6 5 59 0.86 [ 0.70, 0.95 ] 0.91 [ 0.81, 0.97 ]
Witkowski 2016 127 24 13 96 0.91 [ 0.85, 0.95 ] 0.80 [ 0.72, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. KER - RCM - other.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 13 KER RCM other
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Longo 2013 51 12 0 66 1.00 [ 0.93, 1.00 ] 0.85 [ 0.75, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. KER - dermoscopy - equivocal.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 14 KER dermoscopy equivocal
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 128 25 12 95 0.91 [ 0.86, 0.95 ] 0.79 [ 0.71, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 15. Malignant melanoma (MM)2 - RCM - equivocal (non-pigmented) not in melanoma review.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 15 Malignant melanoma (MM)2 RCM equivocal (non-pigmented) not in melanoma review
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 6 8 6 240 0.50 [ 0.21, 0.79 ] 0.97 [ 0.94, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. BCC - RCM score at ≥ 3 - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 16 BCC RCM score at≥ 3 in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Curchin 2011 6 0 3 41 0.67 [ 0.30, 0.93 ] 1.00 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 17. BCC - RCM score at NR (likely ≥ 3) - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 17 BCC RCM score at NR (likely≥ 3) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pellacani 2014a (cons) 19 62 0 227 1.00 [ 0.82, 1.00 ] 0.79 [ 0.73, 0.83 ]
Pellacani 2014b (doc) 19 91 0 73 1.00 [ 0.82, 1.00 ] 0.45 [ 0.37, 0.52 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. BCC - Guitera 2-step algorithm (significant chars for BCC) - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 18 BCC Guitera 2-step algorithm (significant chars for BCC) image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guitera 2012 34 16 18 288 0.65 [ 0.51, 0.78 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. BCC - no algorithm (significant characteristics) - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 19 BCC no algorithm (significant characteristics) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Castro 2015 45 2 0 7 1.00 [ 0.92, 1.00 ] 0.78 [ 0.40, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 20. BCC - no algorithm (significant characteristics) - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 20 BCC no algorithm (significant characteristics) image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Longo 2013 27 1 0 102 1.00 [ 0.87, 1.00 ] 0.99 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. BCC - no algorithm (selected characteristics) - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 21 BCC no algorithm (selected characteristics) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Incel 2015 51 0 5 66 0.91 [ 0.80, 0.97 ] 1.00 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 22. BCC - no algorithm (selected characteristics) - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 22 BCC no algorithm (selected characteristics) image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nori 2004 78 15 5 54 0.94 [ 0.86, 0.98 ] 0.78 [ 0.67, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 23. BCC - no algorithm (observer diagnosis) - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 23 BCC no algorithm (observer diagnosis) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rao 2013 20 26 5 267 0.80 [ 0.59, 0.93 ] 0.91 [ 0.87, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 24. BCC - no algorithm (observer diagnosis) - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 24 BCC no algorithm (observer diagnosis) image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 14 20 1 65 0.93 [ 0.68, 1.00 ] 0.76 [ 0.66, 0.85 ]
Longo 2013 25 3 0 101 1.00 [ 0.86, 1.00 ] 0.97 [ 0.92, 0.99 ]
Rao 2013 14 7 13 289 0.52 [ 0.32, 0.71 ] 0.98 [ 0.95, 0.99 ]
Witkowski 2016 97 9 17 137 0.85 [ 0.77, 0.91 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. BCC - hand-held RCM - no algorithm (significant characteristics).
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 25 BCC hand-held RCM no algorithm (significant characteristics)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Castro 2015 45 2 0 7 1.00 [ 0.92, 1.00 ] 0.78 [ 0.40, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. SCC - no algorithm (selected characteristics) in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 28 SCC no algorithm (selected characteristics) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Incel 2015 9 4 2 107 0.82 [ 0.48, 0.98 ] 0.96 [ 0.91, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. SCC - no algorithm (observer diagnosis) - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 29 SCC no algorithm (observer diagnosis) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rao 2013 16 7 23 272 0.41 [ 0.26, 0.58 ] 0.97 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 30. SCC - no algorithm (observer diagnosis) - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 30 SCC no algorithm (observer diagnosis) image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Longo 2013 5 0 0 124 1.00 [ 0.48, 1.00 ] 1.00 [ 0.97, 1.00 ]
Rao 2013 31 23 11 258 0.74 [ 0.58, 0.86 ] 0.92 [ 0.88, 0.95 ]
Witkowski 2016 10 4 3 243 0.77 [ 0.46, 0.95 ] 0.98 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. KER - RCM at ≥ 3 - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 33 KER RCM at≥ 3 in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Curchin 2011 19 3 3 25 0.86 [ 0.65, 0.97 ] 0.89 [ 0.72, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. KER - no algorithm (observer diagnosis) - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 36 KER no algorithm (observer diagnosis) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rao 2013 57 37 16 208 0.78 [ 0.67, 0.87 ] 0.85 [ 0.80, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. KER - no algorithm (observer diagnosis) - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 37 KER no algorithm (observer diagnosis) image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 30 6 5 59 0.86 [ 0.70, 0.95 ] 0.91 [ 0.81, 0.97 ]
Longo 2013 51 12 0 66 1.00 [ 0.93, 1.00 ] 0.85 [ 0.75, 0.92 ]
Rao 2013 66 34 12 211 0.85 [ 0.75, 0.92 ] 0.86 [ 0.81, 0.90 ]
Witkowski 2016 127 24 13 96 0.91 [ 0.85, 0.95 ] 0.80 [ 0.72, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. KER - no algorithm (excise decision) - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 38 KER no algorithm (excise decision) in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rao 2013 62 94 11 151 0.85 [ 0.75, 0.92 ] 0.62 [ 0.55, 0.68 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. KER - no algorithm (excise decision) - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 39 KER no algorithm (excise decision) image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rao 2013 70 52 8 193 0.90 [ 0.81, 0.95 ] 0.79 [ 0.73, 0.84 ]
Witkowski 2016 137 40 3 80 0.98 [ 0.94, 1.00 ] 0.67 [ 0.57, 0.75 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. BCC - by observer - high - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 40 BCC by observer high in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Castro 2015 45 2 0 7 1.00 [ 0.92, 1.00 ] 0.78 [ 0.40, 0.97 ]
Pellacani 2014a (cons) 19 62 0 227 1.00 [ 0.82, 1.00 ] 0.79 [ 0.73, 0.83 ]
Pellacani 2014b (doc) 19 91 0 73 1.00 [ 0.82, 1.00 ] 0.45 [ 0.37, 0.52 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. BCC - by observer - high - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 41 BCC by observer high image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 14 20 1 65 0.93 [ 0.68, 1.00 ] 0.76 [ 0.66, 0.85 ]
Guitera 2012 34 16 18 288 0.65 [ 0.51, 0.78 ] 0.95 [ 0.92, 0.97 ]
Longo 2013 25 3 0 101 1.00 [ 0.86, 1.00 ] 0.97 [ 0.92, 0.99 ]
Rao 2013 14 7 13 289 0.52 [ 0.32, 0.71 ] 0.98 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 42. BCC - by observer - low - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 42 BCC by observer low in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Curchin 2011 6 0 3 41 0.67 [ 0.30, 0.93 ] 1.00 [ 0.91, 1.00 ]
Rao 2013 20 26 5 267 0.80 [ 0.59, 0.93 ] 0.91 [ 0.87, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. BCC - by observer - low - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 43 BCC by observer low image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 13 10 2 75 0.87 [ 0.60, 0.98 ] 0.88 [ 0.79, 0.94 ]
Nori 2004 78 15 5 54 0.94 [ 0.86, 0.98 ] 0.78 [ 0.67, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 44. BCC - by observer - NR - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 44 BCC by observer NR in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Incel 2015 51 0 5 66 0.91 [ 0.80, 0.97 ] 1.00 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. BCC - by observer - NR - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 45 BCC by observer NR image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 97 9 17 137 0.85 [ 0.77, 0.91 ] 0.94 [ 0.89, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. SCC - by observer - low - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 47 SCC by observer low in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rao 2013 16 7 23 272 0.41 [ 0.26, 0.58 ] 0.97 [ 0.95, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. SCC - by observer - NR - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 48 SCC by observer NR in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Incel 2015 9 4 2 107 0.82 [ 0.48, 0.98 ] 0.96 [ 0.91, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. SCC - by observer - high - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 49 SCC by observer high image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Longo 2013 5 0 0 124 1.00 [ 0.48, 1.00 ] 1.00 [ 0.97, 1.00 ]
Rao 2013 31 23 11 258 0.74 [ 0.58, 0.86 ] 0.92 [ 0.88, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 50. SCC - by observer - NR - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 50 SCC by observer NR image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 10 4 3 243 0.77 [ 0.46, 0.95 ] 0.98 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 52. KER - by observer - low - in person.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 52 KER by observer low in person
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Curchin 2011 19 3 3 25 0.86 [ 0.65, 0.97 ] 0.89 [ 0.72, 0.98 ]
Rao 2013 57 37 16 208 0.78 [ 0.67, 0.87 ] 0.85 [ 0.80, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 53. KER - by observer - high - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 53 KER by observer high image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 30 6 5 59 0.86 [ 0.70, 0.95 ] 0.91 [ 0.81, 0.97 ]
Longo 2013 51 12 0 66 1.00 [ 0.93, 1.00 ] 0.85 [ 0.75, 0.92 ]
Rao 2013 66 34 12 211 0.85 [ 0.75, 0.92 ] 0.86 [ 0.81, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 54. KER - by observer - low - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 54 KER by observer low image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farnetani 2015 29 10 6 55 0.83 [ 0.66, 0.93 ] 0.85 [ 0.74, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 55. KER - by observer - NR - image based.
Review: Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults
Test: 55 KER by observer NR image based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Witkowski 2016 127 24 13 96 0.91 [ 0.85, 0.95 ] 0.80 [ 0.72, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Comparison of reflectance confocal microscopy with dermoscopy for the detection of basal cell carcinoma
Test Studies Lesions (cases) Sensitivity (95% CI) Specificity (95% CI)
Any suspicious lesion studies (all studies)
RCM 4 912 0.76 (0.45 to 0.92) 0.95 (0.66 to 0.99)
Dermoscopy 0 - - -
Any suspicious lesion studies (direct comparisons)
RCM 0 - - -
Dermoscopy 0 - - -
Equivocal lesion studies (all studies)
RCM 3 668 0.94 (0.79 to 0.98) 0.85 (0.72 to 0.92)
Dermoscopy 1 260 0.85 (0.77 to 0.91) 0.92 (0.87 to 0.96)
Equivocal lesion studies (direct comparisons)
RCM 1 260 0.85 (0.77 to 0.91) 0.94 (0.89 to 0.97)
Dermoscopy 1 260 0.85 (0.77 to 0.91) 0.92 (0.87 to 0.96)
CI: confidence interval; RCM: reflectance confocal microscopy.
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Table 2. Results by observer experience
Person/image Observer
experience
Studies (n) Lesions (cases) Pooled sensitivity (95%
CI)
Pooled specificity
(95% CI)
Detection of BCC
In person High 3 545 (83) 1.00 (0.96 to 1.00) 0.67 (0.45 to 0.83)
Image High 4 908 (119) 0.86 (0.50 to 0.97) 0.94 (0.86 to 0.98)
Both High 7 1453 (202) 0.98 (0.74 to 1.00) 0.87 (0.71 to 0.95)
In person Low 2 368 (34) 0.75 (0.53 to 0.88) 0.97 (0.64 to 1.00)
Image Low 2 252 (98) 0.92 (0.82 to 0.97) 0.84 (0.75 to 0.90)
Both Low 4 620 (132) 0.85 (0.69 to 0.93) 0.91 (0.81 to 0.96)
In person NR 1 122 (56) 0.91 (0.80 to 0.97) 1.00 (0.95 to 1.00)
Image NR 1 260 (114) 0.85 (0.77 to 0.91) 0.94 (0.78 to 0.97)
Both NR 2 382 (170) 0.88 (0.80 to 0.93) 0.98 (0.74 to 1.00)
Detection of cSCC
In person High 0 0 - -
Image High 2 452 (47) 0.95 (0.06 to 1.00) 0.99 (0.40 to 1.00)
Both High 2 452 (47) 0.95 (0.06 to 1.00) 0.99 (0.40 to 1.00)
In person Low 1 318 (39) 0.41 (0.26 to 0.58) 0.97 (0.95 to 1.00)
Image Low 0 0 - -
Both Low 1 318 (39) 0.41 (0.26 to 0.58) 0.97 (0.95 to 1.00)
In person NR 1 122 (11) 0.82 (0.48 to 0.98) 0.96 (0.91 to 0.99)
Image NR 1 260 (13) 0.77 (0.46 to 0.95) 0.98 (0.96 to 1.00)
Both NR 2 382 (24) 0.79 (0.59 to 0.91) 0.98 (0.96 to 0.99)
Detection of KER
In person High 0 0 - -
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Table 2. Results by observer experience (Continued)
Image High 3 552 (161) 0.94 (0.70 to 0.99) 0.86 (0.82 to 0.90)
Both High 3 552 (161) 0.94 (0.70 to 0.99) 0.86 (0.82 to 0.90)
In person Low 2 368 (95) 0.80 (0.71 to 0.87) 0.85 (0.81 to 0.89)
Image Low 1 90 (35) 0.83 (0.66 to 0.93) 0.85 (0.74 to 0.92)
Both Low 3 458 (130) 0.81 (0.73 to 0.87) 0.85 (0.81 to 0.89)
In person NR 0 0 - -
Image NR 1 260 (140) 0.91 (0.85 to 0.95) 0.80 (0.72 to 0.87)
Both NR 1 260 (140) 0.91 (0.85 to 0.95) 0.80 (0.72 to 0.87)
BCC: basal cell carcinoma; CI: confidence interval; cSCC: cutaneous squamous cell carcinoma; KER: any keratinocyte skin cancer; n:
number; NR: not reported.
Table 3. Comparison of reflectance confocal microscopy with dermoscopy for the detection of squamous cell carcinoma
Test Studies Lesions (cases) Sensitivity (95% CI) Specificity (95% CI)
All lesion studies (all studies)
RCM 1 323 (42) 0.74 (0.58 to 0.86) 0.92 (0.88 to 0.95)
Dermoscopy 0 - - -
All lesion studies (direct comparisons)
RCM 0 - - -
Dermoscopy 0 - - -
Equivocal lesion studies (all studies)
RCM 1 260 (13) 0.77 (0.46 to 0.95) 0.98 (0.96 to 1.00)
Dermoscopy 1 260 (13) 0.77 (0.46 to 0.95) 0.99 (0.96 to 1.00)
Equivocal lesion studies (direct comparisons)
RCM 1 260 (13) 0.77 (0.46 to 0.95) 0.98 (0.96 to 1.00)
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Table 3. Comparison of reflectance confocal microscopy with dermoscopy for the detection of squamous cell carcinoma
(Continued)
Dermoscopy 1 260 (13) 0.77 (0.46 to 0.95) 0.99 (0.96 to 1.00)
CI: confidence interval; RCM: reflectance confocal microscopy.
Table 4. Comparison of reflectance confocal microscopy with dermoscopy for the detection of any skin cancer
KER Studies Lesions (cases) Sensitivity (95% CI) Specificity (95% CI)
Any suspicious lesion studies (all studies)
RCM 2 373 (100) 0.85 (0.77 to 0.91) 0.86 (0.82 to 0.98)
Dermoscopy 0 - - -
Any suspicious lesion studies (direct comparisons)
RCM 0 - - -
Dermoscopy 0 - - -
Equivocal lesion studies (all studies)
RCM 2 360 (175) 0.89 (0.82 to 0.94) 0.85 (0.75 to 0.92)
Dermoscopy 1 260 (140) 0.91 (0.86 to 0.95) 0.79 (0.71 to 0.86)
Equivocal lesion studies (direct comparisons)
RCM 1 260 (140) 0.91 (0.85 to 0.95) 0.80 (0.72 to 0.87)
Dermoscopy 1 260 (140) 0.91 (0.86 to 0.95) 0.79 (0.71 to 0.86)
CI: confidence interval; KER: any keratinocyte skin cancer; RCM: reflectance confocal microscopy.
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A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-asssisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-asssisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-asssisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
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(Continued)
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Table of acronyms used in review text
Acronym Definition
BCC Basal cell carcinoma
BPC Between-person comparative (study)
CAD Computer-assisted diagnosis
cSCC Cutaneous squamous cell carcinoma
DEJ Dermoepidermal junction
DTA Diagnostic test accuracy
ENT Ear, nose, and throat
FP False positive
GP General practitioner
KER Any keratinocyte skin cancer
LM Lentigo maligna
MEL Invasive melanoma or melanoma in situ
MM Malignant melanoma
NHS National Health Service
NICE National Institute for Health and Care Excellence
NIHR National Institute for Health Research
NML Non-melanocytic lesion
OCT Optical coherence tomography
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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(Continued)
QUADAS Quality Assessment of Diagnostic Accuracy Studies
RCM Reflectance confocal microscopy
RCT Randomised controlled trial
RDEB Recessive dystrophic epidermolysis bullosa
ROC Receiver operating characteristic
SCC Squamous cell carcinoma
TN True negative
Appendix 3. Proposed sources of heterogeneity
1. Population characteristics
• general versus higher risk populations
• participant population: primary/secondary/specialist unit
• lesion suspicion: general suspicion/atypical/equivocal/not reported
• lesion type: any pigmented; melanocytic
• inclusion of multiple lesions per participant
• ethnicity
2. Index test characteristics
• type of test or algorithm used for test interpretation within each ’group’ of tests
• the nature of and definition of criteria for test positivity
• diagnosis in-person versus image-based diagnosis
• observer experience with the index test
• approaches to lesion preparation (e.g. the use of oil or antiseptic gel for dermoscopy)
3. Reference standard characteristics
• reference standard used
• whether histology reporting meets pathology reporting guidelines
• use of excisional versus diagnostic biopsy
• whether two independent dermatopathologists reviewed histological diagnosis
4. Study quality
• consecutive or random sample of participants recruited
• index test interpreted blinded to the reference standard result
• index test interpreted blinded to the result of any other index test
• presence of partial or differential verification bias (whereby only a sample of those subject to the index test were verified by the
reference test or by the same reference test with selection dependent on the index test result)
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• use of an adequate reference standard
• overall risk of bias
Appendix 4. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
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43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
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95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
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29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
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81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
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30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
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82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
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#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
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#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
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#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database: CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
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S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
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S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: ( MEETING ABSTRACT OR PROCEEDINGS PAPER )
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Appendix 5. Full text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case-control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epitheliomac
◦ SCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
pigmented skin lesion/nevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscopy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
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(Continued)
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign-
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLNB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 6. Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Participant selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo
a test should be included in a study, allowing for the intended use of that test within the context of the study. We considered studies that
separately sampled malignant and benign lesions to have used a case-control design; and those that supplemented a series of suspicious
lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types, particular lesion sites, or that excluded lesions on
the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at high risk of bias.
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In judging the applicability of participant populations to the review question, we considered restriction to particular lesion populations,
such as melanocytic, nodular, high risk, or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to
contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We considered
studies that include a high number of lesions in relation to the number of study to be less representative than studies conducted in a
more general population participants (i.e. if the difference between the number of included lesions and number of included participants
is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation, the interpretation of the index test blinded to the result of the
reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the original index test
interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference standard is known; however,
studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low risk of bias,
we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation. An item
was also added to assess the presence of blinding between interpretations of different algorithms, however this item was not included
in the overall assessment of risk of bias.
Prespecification of the index test threshold was considered present if the study clearly reported that the threshold used was not data
driven (i.e. was not based on study results). Studies that did not clearly describe the threshold used but that required clinicians to record
a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies reporting accuracy for multiple
numeric thresholds, where receiver operating characteristic (ROC) analysis was used to select the threshold, or that reported accuracy
for the presence of independently significant lesion characteristics with no separate test set of lesions were considered at high risk of
bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would be in a
clinical practice setting (i.e. in person or face-to-face with the participant), and by a single observer as opposed to a consensus decision
or mean across multiple observers. Image-based studies were considered to be high concern, although RCM image interpretations
where the observer was also supplied with a clinical or dermoscopic image of the lesion along with some participant characteristics were
considered ’unclear.’
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion character-
istics that were considered to be indicative for skin cancer, particularly where established algorithms or checklists were not used. Studies
were considered of low concern if the threshold used was established in a prior study or sufficient threshold details were presented to
allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test interpreter
as ’experienced’ or ’expert’ in RCM to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of
level of clinical suspicion. In reality, both partial and differential verification bias are likely. Partial verification bias may occur where
histology is the only reference standard used, and only those participants with a certain degree of suspicion of malignancy based on
the result of the index test undergo verification, the others either being excluded from the study or defined as being disease negative
without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious
lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with benign-appearing
lesions but instead follow them up for a period of time to determine whether any malignancy subsequently develops (these would be
false negatives on the index test). We defined an ’adequate’ reference standard as: all disease positive participants having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease
negative participants have received a histological diagnosis, with up to 20% undergoing at least three months’ follow-up of benign-
appearing lesions.
A further challenge is the potential for incorporation bias (i.e. where the result of the index test is used to help determine the reference
standard diagnosis). It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on
pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation. Although inclusion
of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation
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of the histopathology reference standard is not normal practice, and enforcement of such conditions would significantly limit the
generalisability of the study results. For studies evaluating RCM, this item was divided into two questions, first whether the reference
standard was blinded to the index test result (RCM), and second whether it was blinded to the clinical diagnosis. Only the response to
the first part (i.e. blinding to RCM) was included in our overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around applicability if they
used expert diagnosis (with no follow-up) as a reference standard in any participant, or did not report histology interpretation by a
dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to each other in
time as possible to avoid changes in lesion over time. For lesions with a histological reference standard, we have defined a one-month
period as an appropriate interval between application of the index test and the reference standard. For studies using clinical follow-up,
a minimum three-month follow-up period has been defined as at low risk of bias for detecting false negatives.
In assessing whether all participants were included in the analysis, we considered studies at high risk of bias if participants were excluded
following recruitment.
Comparative domain
A comparative domain was added to the QUADAS-2 checklist for studies comparing the accuracy of RCM and dermoscopy. Items were
included to assess the presence of blinding of interpretation between tests, and to specify a maximum of one month interval between
application of index tests, as intervals greater than these may be accompanied by changes in tumour characteristics. As it would not be
normal practice for RCM to be interpreted blinded to the clinical or dermoscopic diagnosis, the scoring of this item did not contribute
to our overall assessment of risk of bias. We also considered whether both tests were applied and interpreted in a clinically applicable
manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
Participant selection (1) risk of bias
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g.
• ’difficult to diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g. ’difficult to diagnose’ lesions, or where disagreement between
evaluators was observed
Unclear - if not clearly reported but there is suspicion that difficult
to diagnose lesions may have been excluded
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4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
• A) were the same participant selection criteria used for
those allocated to each test?
• B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A)
• Yes - if same selection criteria were used for each index test,
No - if different selection criteria were used for each index test,
Unclear - if selection criteria per test were not described, N/A -
if only 1 index test was evaluated or all participants received all
tests
For B)
• Yes - if adequate randomisation procedures are described,
No - if inadequate randomisation procedures are described,
Unclear - if the method of allocation to groups is not described
(a description of ’random’ or ’randomised’ is insufficient), N/A -
if only 1 index test was evaluated or all participants received all
tests
For C)
• Yes - if appropriate methods of allocation concealment are
described, No - if appropriate methods of allocation concealment
are not described, Unclear - if the method of allocation
concealment is not described (sufficient detail to allow a definite
judgement is required), N/A - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
For non-comparative and within-person comparative studies
1. If answers to all of questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) ’Yes’:
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’:
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’:
For non-comparative and within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
Participant selection (1) concerns regarding applicability
1) Are the included participants and chosen study setting appro-
priate to answer the review question, i.e. are the study results gen-
eralisable?
• This item is not asking whether exclusion of certain
participant groups might bias the study’s results (as in ’Risk of
bias’ above), but is asking whether the chosen study participants
and setting are appropriate to answer our review question.
Because we are looking to establish test accuracy in both primary
presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be
unclear as to whether the study can appropriately answer either
question
• For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a skin
lesion or B) referred participants, and respond to the questions
in either A) or B) accordingly. If the study gives insufficient
details, please respond Unclear to both parts of the question
A) For studies that will contribute to the analysis of partic-
ipants with a primary presentation of a skin lesion (i.e. test
naive)
Yes - if participants included in the study appear to be generally
representative of those who might present in a usual practice set-
ting
No - if study participants appear to be unrepresentative of usual
practice, e.g. in terms of severity of disease, demographic features,
presence of differential diagnosis or comorbidity, setting of the
study, and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
Yes - if study participants appear to be representative of those who
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might be referred for further investigation. If the study focuses
only on those with equivocal lesions, for example, we would sug-
gest that this is not representative of the wider referred population
No - if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1) or 2) ’Yes’:
2. If the answer to question 1) or 2) ’No’:
3. If the answer to question 1) or 2) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
Index test (2) risk of bias (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
3) For within-person comparisons of index tests or testing strate-
gies (i.e. > 1 index test applied per participant): was each index
test result interpreted without knowledge of the results of other
index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
N/A - if only 1 index test was evaluated
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Could the conduct or interpretation of the index test have intro-
duced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1) and 2) ’Yes’:
2. If answers to either questions 1) or 2) ’No’:
3. If answers to either questions 1) or 2) ’Unclear’:
For within-person comparative studies
1. If answers to all questions 1), 2), for any index test and 3)
’Yes’:
2. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’No’:
3. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’Unclear’:
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
Index test (2) concern about applicability
1) Was the diagnostic threshold to determine presence or absence
of disease established in a previously published study?
E.g. previously evaluated/established
• algorithm/checklist used
• lesion characteristics
• objective (usually numerical) threshold used
Yes - if a previously evaluated/established tool to aid diagnosis
was used or if the diagnostic threshold used was established in a
previously published study
No - if an unfamiliar/new tool to aid diagnosis was used, if no par-
ticular algorithm was used, or if the objective threshold reported
was chosen based on results in the current study
Unclear - if insufficient information was reported
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
Yes - If the criteria for diagnosis were reported in sufficient detail
to allow replication
No - if the criteria for diagnosis were not reported in sufficient
detail to allow replication
Unclear - If some but not sufficient information on criteria for
diagnosis to allow replication were provided
3) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in
the use of the test
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported in
sufficient detail to judge or if examiners were described as ’Expert’
with no further detail given
N/A - if system-based diagnosis, i.e. no observer interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1), 2), and 3) ’Yes’:
2. If answers to questions 1), 2), or 3) ’No’:
3. If answers to questions 1), 2), or 3) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
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Reference standard (3) risk of bias
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease positive - 1 or more of the following:
• histological confirmation of malignancy following biopsy
or lesion excision
• clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to a
histological diagnosis of skin cancer
B) Disease negative - 1 or more of the following:
• histological confirmation of absence of malignancy
following biopsy or lesion excision in at least 80% of disease-
negative participants
• clinical follow-up of benign-appearing lesions for a
minimum of 3 months following the index test in up to 20% of
disease-negative participants
A) Disease positive
Yes - if all participants with a final diagnosis of malignancy un-
derwent 1 of the listed reference standards
No - If a final diagnosis of malignancy for any participant was
reached without histopathology
Unclear - if themethod of final diagnosis was not reported for any
participant with a final diagnosis of malignancy or if the length
of clinical follow-up used was not clear or if a clinical follow-up
reference standard was reported in combination with a partici-
pant-based analysis and it was not possible to determine whether
the detection of a malignant lesion during follow-up is the same
lesion that originally tested negative on the index test
B) Disease negative
Yes - If at least 80% of benign diagnoses were reached by histology
and up to 20% were reached by clinical follow-up for a minimum
of 3 months following the index test
No - ifmore than20%of benigndiagnoseswere reachedby clinical
follow-up for a minimum of 3 months following the index test or
if clinical follow-up period was less than 3 months
Unclear - if the method of final diagnosis was not reported for
any participant with benign or non-melanoma diagnosis
2) Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
tests, this item will be retained
Yes - if the reference standard diagnosis was reached blinded to
the index test result
No - if the reference standard diagnosis was reached with knowl-
edge of the index test result
Unclear - if blinded reference test interpretation was not clearly
reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1) ’Yes’:
2. If answer to question 1) ’No’:
3. If answer to question 1) ’Unclear’:
For all other tests
1. If answers to questions 1) and 2) ’Yes’:
2. If answers to questions 1) or 2) ’No’:
3. If answers to questions 1) or 2) ’Unclear’:
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
REFERENCE STANDARD (3) CONCERN ABOUT APPLICABILITY
1) Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
Yes - if expert opinion was not used as a reference standard for
any participant
No - if expert opinion was used as a reference standard for any
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examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
participant
Unclear - if not clearly reported
2) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to both questions 1), 2), ’Yes’:
2. If answers to any 1 of questions 1), 2), ’No’:
3. If answers to any 1 of questions 1), 2), ’Unclear’:
***For teledermatology studies only
1. If answers to all questions 1) and 3) ’Yes’:
2. If answers to questions 1) or 3) ’No’:
3. If answers to questions 1) or 3) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
***For teledermatology studies only
1. Concern is low
2. Concern is high
3. Concern is unclear
Flow and timing (4): risk of bias
1) Was there an appropriate interval between index test and ref-
erence standard?
A) For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 3 months’ follow-
up following application of index test(s)?
A)
Yes - if study reports ≤ 1 month between index and reference
standard
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
B)
Yes - if study reports ≥ 3 months’ follow-up
No - if study reports < 3 months’ follow-up
Unclear - if study does not report the length of clinical follow-up
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear- if not clearly reported
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report the interval between index tests
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1), 2), and 3) ’Yes’:
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
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2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
For within-person comparative studies
1. If answers to all questions 1), 2), 3), and 4) ’Yes’:
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’:
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’:
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma
Appendix 7. Details of RCM algorithms and diagnostic thresholds for diagnosis
Castro 2015
BCC
Guitera 2012
(2 step algorithm to identify
BCC then MM)
Longo 2013
BCC (and MM)
Nori 2004 (based on
Gonzalez 2002)
BCC
Previously published RCM cri-
teria assessed (cites Agero 2006;
Nori 2004; Guitera 2012)
Selected characteristics chosen;
≥ c3 RCM criteria present, in-
cluding either presence of:
• ’dark silhouettes’ or
• ’bright tumour islands’
Additional criteria assessed:
• ’streaming’ polarisation of
nuclei in neoplastic aggregates
along the same axis of
orientation;
• ’peripheral palisading’ of
nuclei at the tumour islands’
periphery;
• dark ’peritumoral clefts’
around the tumour islands;
• fibrotic stroma with
’thickened collagen bundles’;
• dilated and tortuous
’linear blood vessels’ and
’coiled blood vessels’;
• ’bright dendritic
structures’ within tumour
islands; and
• ’bright round cells’ in the
stroma
Evaluated 47 RCM features
(referenced to a number of prior
studies) and conducted multi-
variate analysis on the train-
ing set of lesions to identify in-
dependently significant features
for MM and for BCC; assume
presence of any one indicated
T+)
Correct identification as MM
or BCC (based on indepen-
dently significant features as
identification from training set)
For BCC:
• polarised in the
honeycomb
• linear telangiectasia-like
horizontal vessels
• basaloid cord or nodule
• epidermal shadow
• convoluted glomerular-
like vessels
• non-visible papillae
• cerebriform nests
• disarray of the epidermal
layer
47 RCM features recorded;
multivariate analysis id 4 pos-
itive independent significant
features for BCC
• tumour islands (dark
silhouettes or tightly packed
basaloid islands)
• cauliflower architecture;
• bright filaments within
the tumour islands; and
• presence of bright
collagen
Selected 5 criteria from a num-
ber of morphologic character-
istics previously investigated by
the same group, on the basis
that theywere ’easily andunam-
biguously detected by non-der-
matopathologists and a novice
reviewer’
Data presented for ≥ 2, ≥ 3,≥
4, 5 characteristics present
• elongated monomorphic
basaloid nuclei;
• polarisation of these
nuclei along the same axis of
orientation;
• prominent inflammatory
infiltrate;
• increased dermal
vasculature;
• pleomorphism of the
overlying epidermis indicative
of actinic changes
Incel 2015
BCC/SCC
Results based on ’observer diagnosis’
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Selected characteristics from
to assist correct diagnosis of
different lesion types (cites
Malvehy 2012; Eichert 2010;
Ahlgrimm-Siess 2010; Röwert-
Huber 2007; Ahlgrimm-Siess
2011)
Characteristics listed for BCC
included:
• dark silhouettes in
dermis,
• bright tumour islands at
DEJ and in the dermis;
• cleft-like dark areas;
• dendritic cells,
• bright round cells,
• canalicular vessels
Characteristics listed for SCC
included: refractile squam/crust
in stratum corneum and nu-
cleated cells with dark centre
(parakeratotic)cells;
• atypical honeycomb
pattern, disarranged pattern at
stratum granulosum layer;
• large, round, nucleated
cells at the granular layer
(dyskeratotic cells);
• dendritic cells at the
granular layer and small edged
papillae at DEJ
Curchin 2011: applied RCM score: ≥ 3 for suspected melanomas and LM score for suspected LM
of the face (Guitera 2010); reported observer correct diagnosis of BCC; no further details presented
Farnetani 2015: evaluators completed a ’pattern description’ (presence/absence of a number of RCM
features) and gave an overall diagnosis of malignant (melanoma or BCC) or benign
Discriminant analysis also used to identify features independently associated with malignancy (and
with MM and BCC separately)
3 more frequently observed in BCC were:
• basaloid cord-like structures,
• presence of ulceration,
• a specific DEJ pattern
Pellacani 2014: NR; Pellacani 2005 algorithm used for diagnosis of melanoma
Rao 2013: observers gave diagnosis (MM/BCC/SCC) and excise decision (no further details)
Witkowski 2016: report correct diagnosis (MM/BCC/SCC) and excise decision (no further details)
BCC: basal cell carcinoma; DEJ: dermoepidermal junction; LM: lentigo maligna; MM: malignant melanoma; RCM: reflectance
confocal microscopy; SCC: squamous cell carcinoma; T+: test positive
Appendix 8. Summary study details by lesion population
Study author
Outcomes re-
ported
Study type
Country
Setting
Inclusion cri-
teria
n partici-
pants/lesions
Index tests
(algorithm)
Diagnostic
approach
Observer
qual (n); expe
Additional
data available
Reference
standard
Final
diagnoses
Exclusions
Any suspicious lesion
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(Continued)
Curchin 2011
BCC
KER
(MEL)
NC
P-CS
Australia
Secondary
People sched-
uled for minor
excision
42/50 Vi-
vascope 1500;
Observer dx
(RCM score
for suspected
melanomas)
In person (sin-
gle observer)
Observer qual
NR; n = NR
Described
as novice to
RCM analysis
af-
ter completing
a RCM anal-
ysis course in
Modena, Italy
Der-
moscopic and
RCM images
were aligned
over the top of
each other
Histology
alone
MM 12; MiS
1; BCC: 9;
cSCC: 6 (in-
cluded SK or
AK, or both)
; ’benign’ diag-
noses: 23
Reported cor-
rect dx of all
6 SCC or pre-
cursors (not
disaggregated)
Guitera 2012
BCC
(MEL)
WPC
NR-CS
Australia/
Italy
Special-
ist clinic/sec-
ondary
People with
suspicious le-
sions, includ-
ing those on
face and neck
suspicious for
LM, and
requiring his-
tology to rule
out an epithe-
lial tumour or
an MM; pre-
dominantly
melanocytic
or suspicious
for BCC
663/710
356 lesions
randomised to
’test set’ in-
cluded here
Vivas-
cope 1500;No
algorithm (in-
depen-
dently signif-
icant features
for BCC)
Image-
based (single
observer)
Dermatolo-
gist (n =2); de-
scribed as ex-
pert observers
RCM guided
by dermo-
scopic find-
ings but inter-
pretation
blinded to all
but lesion lo-
ca-
tion and par-
ticipant age
Histology
alone
MEL
105; BCC: 52;
cSCC: 9; BN
132; SN 16;
AK 8; 31 be-
nignmacule of
the face and 3
DF
BCC: 2 MM
and 2 SCC
were FP
Pellacani
2014b (doc)
BCC
(MEL)
NC
P-CS
Italy
Specialist
clinic
People
requesting a
mole check or
with suspicion
of melanoma
who were re-
ferred to PLC
clinic. Docu-
mentation
group
(doc) included
lesions with
consistent
clinical or der-
moscopic cri-
171/184
(1/184 did not
undergo
RCM)
Vivascope
1500; ob-
server dx (as-
sumed RCM
score for sus-
pected
melanomas)
In person (sin-
gle observer)
Observer qual
NR (n = 1); dx
made at ’con-
focal unit’
RCM reader
was aware that
lesions were
dermoscop-
ically atypical
but blinded to
’RCM docu-
mentation’ or
’RCM consul-
tation’
Histology
alone (docu-
mentation
group)
MM 13; MiS
9; BCC: 19; 1
melanoma
metas-
tases; BN 121;
SN 8; SK or
other keratotic
7; other be-
nign 5
-
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teria, or both,
for melanoma
dx
Rao 2013
BCC
SCC
KER
(MEL)
NC
NR-CS
USA
Secondary
All lesions re-
moved for cos-
metic or med-
ical rea-
sons that were
imagedusing a
con-
focal scanning
microscope
NR/334
Reader 1
(novice) eval-
uated 318 le-
sions; reader 2
(expert) evalu-
ated 323 le-
sions; 284
were exam-
ined by both
readers
Vi-
vascope 1500;
No algorithm
(correct dx
of each malig-
nancy; overall
observer dx of
malignancy)
Image-
based (single
observer)
Observer qual
NR (n = 2);
reader 1 had 1
year’ RCM ex-
perience at the
start
of the study;
reader 2 had
> 9 years’ ex-
perience with
RCM
dx was based
on the der-
moscopic im-
age and confo-
cal mi-
croscopy eval-
uation
Histology
alone
MM 8;
melanoma (in
situ); 1; BCC:
27; cSCC: 42;
BN 176; SK
22; AK 24; 23
other
BCC: 4 SCC
were FP; SCC:
9
BCCs picked
up as SCCs
were con-
sidered TN as
per Methods
Equivocal lesion studies
Farnetani
2015
BCC
(MEL)
NC
R-CS
Italy
Secondary
Diagnos-
tically equivo-
cal lesions ex-
cised due to
clinical or der-
moscopic sus-
picion
of melanoma,
where
a specific clin-
ical and der-
moscopic dx
could not be
rendered with
certainty
NR/100 Vivas-
cope 1500; no
algorithm (ob-
server dx - pat-
tern descrip-
tion and di-
agnostic judg-
ment)
Im-
age based (sin-
gle observer)
Dermatologist
(n = 9); 6 ex-
perienced (≥
3 years’ RCM
expe-
rience) and 3
’recent’ RCM
users. Expe-
rienced reader
randomly se-
lected for pri-
mary analysis
Der-
moscopic im-
age provided;
no additional
clinical infor-
mation
(e.g. age and
melanoma or
lesion history)
Histology
alone
MEL
20; BCC: 15;
SK 7; BN 55;
AK 3
BCC: 14 MM
FP
Pellacani
2014a (cons)
BCC
NC
P-CS
Italy
People
requesting a
252/309
1/308 did not
Vivascope
1500; ob-
Observer qual
NR (n = 1); dx
Histology plus
FU
-
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(Continued)
(MEL) Specialist
clinic
mole check or
with suspicion
of melanoma
who were re-
ferred
to PLC clinic.
Consultation
group (cons)
included
lesions requir-
ing an out-
come decision
from RCM
(dx could not
be reached on
clinical or der-
moscopic cri-
teria, or both)
undergo
RCM
server dx (as-
sumed RCM
score for sus-
pected
melanomas)
In person (sin-
gle observer)
made at ’con-
focal unit’
RCM reader
was aware that
lesions were
dermoscop-
ically atypical
but blinded to
’RCM docu-
mentation’ or
’RCM consul-
tation’
(cons group)
; 227/308 re-
ferred for se-
quential dig-
ital FU; 28
later excised;
MM 2; MiS 4;
BCC: 19; BN
71; SN 5; be-
nign NML 8;
199 benign on
FU
Witkowski
2016
BCC
SCC
MM
WPC-tests
R-CS
Italy
Secondary
Clin-
ically equivo-
cal ’pink’ cuta-
neous le-
sions with ab-
sent pigmen-
tation or con-
taining < 10%
pigment and
absence of pig-
ment network
NR/260 Vivascope
1500; no algo-
rithm (correct
dx of each ma-
lignancy)
Dermoscopy
Image-
based (single
observer)
Der-
matologist (as-
sumed; n = 2,
1 dermoscopy
1 RCM); ex-
perience NR
No additional
information
provided
Histology
alone
MEL
12; BCC: 114;
cSCC: 13; 1
syringoid
eccrine carci-
noma; benign
keratotic 25;
BN 47; SN 6;
DF 18; other
benign 24
BCC: 1 SCC
FP
Other lesion populations
Castro 2015
BCC
WPC
NR-CS
Brazil and
USA
Specialist
clinic
People with ≥
1 skin lesions
deemed suspi-
cious for BCC
based on clin-
ical and der-
moscopic ex-
amination
NR/54 Vivascope
1500 vs Vivas-
cope 3000
(no algorithm;
≥ 3 character-
istics present)
Unclear
if image based;
consensus of 2
Derma-
tologist (n = 1)
; experienced
with RCM ex-
amination and
supervised by
skin cancer ex-
pert
Clinical, der-
moscopic and
RCM imaging
performed by
same derma-
tologist
Histology
BCC: 45; ’be-
nign’
diagnoses: 9
38 of original
92 lesions ex-
cluded as only
ac-
cessible to Vi-
vascope 3000
(mostly facial)
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Incel 2015
BCC
SCC
NC
P-CS
Turkey
Secondary
Peo-
ple with non-
pigmented
suspected tu-
moural lesions
or prolif-
erative skin le-
sions and with
a
vascular struc-
ture on der-
moscopic ex-
amination
114/122 Vivas-
cope 3000 (no
algorithm; se-
lected charac-
teris-
tics; correct dx
of BCC/SCC)
Unclear if im-
age-based; un-
clear if single
observer)
Observer qual
NR (n = NR)
; states “First
60 lesions sub-
jected to
blinded eval-
uation by 2
observers,” no
further details
provided
Histology
BCC:
56; cSCC: 9;
KA 3; SK 11;
AK 8; BD 7;
and 22 other
benign non-
pigmented tu-
mours
BCC: all
SCCs consid-
ered test nega-
tive
Longo 2013
BCC
SCC
KER
(MEL)
NC
R-CS
Italy
Special-
ist clinic/sec-
ondary
Clin-
ically nodular
lesions
(defined as cu-
taneous palpa-
ble/super-
ficial seated le-
sions and not
subcutaneous
ones) that un-
derwent exci-
sion
140/140 Vivascope
1500 (NR but
assumed to be
used; correct
dx of BCC/
SCC)
Image-
based (single
observer)
Dermatol-
ogist (n = 1);
5 years’ experi-
ence in RCM
Blinded to
dermoscopy
Histology
NM23; BCC:
28; cSCC: 6;
Other malig-
nant: 9
melanoma
metastases; SK
14; BN 32 in-
cluding 7 SN)
; 5 vascular; 6
other benign
Non evaluable
and non-spe-
cific results ex-
cluded (n =
11); including
1 BCC and 1
SCC
Nori 2004
BCC
WPC
CCS
USA and
Spain
Secondary/
private clinic
Biopsy
confirmed
BCC and con-
venience sam-
ple of non-
BCC
with ’range of
commondiag-
noses’
145/152
105 had VI dx
Vivas-
cope 1000 (no
algorithm; se-
lected charac-
teristics; ≥ 3
present)
VI (clinical
photographs;
high/
medium/
low probabil-
ity BCC)
Image-
based (single
observer)
Observer qual
NR (n = 1);
’novice confo-
cal reviewer’
Blinded inter-
pretation
Histology or
expert dx; 15/
65 benign had
clinical dx
BCC: 83 ( 58
in VI analysis)
; cSCC: 4; ’be-
nign’ dx: 65
BCC: could
not disaggre-
gate SCC re-
sult (n = 4)
from rest ofD-
group
AK: actinic keratosis; BCC: basal cell carcinoma; BD: Bowen’s disease; BN: benign naevi; BPC: between-person comparison (of tests);
CCS: case-control study; Cons: consensus diagnosis; CS: case series; cSCC: cutaneous squamous cell carcinoma; DF: dermatofibroma;
dx: diagnosis; exp: experience; FP: false positive; FU: follow-up; LS: lentigo simplex; n: number; NC: non-comparative; NR: not
reported; P: prospective; PLC: pigmented lesion clinic;MEL: invasivemelanoma or atypical intraepidermalmelanocytic variants;MiS:
melanoma in situ (or lentigo maligna); MM: malignant (invasive) melanoma; qual: qualification; R: retrospective; RCM: reflectance
confocal microscopy; SK: seborrhoeic keratosis; SN: Spitz nevi; VI: visual inspection; WPC: within-person comparison (of tests)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the primary objective, study populations that could not be clearly identified as either ’any suspicious lesion’ or ’equivocal lesions’
were considered separately as ’other lesion’ studies.
Secondary objectives have been tailored to the individual test, with three objectives added: to compare the accuracy of RCM to
dermoscopy where both tests have been evaluated in the same studies; to determine the diagnostic accuracy of individual algorithms
for RCM; and to determine the effect of observer experience.
The secondary objective has been changed from “for the detection of any skin cancer” to “for the detection of any skin cancer in adults,
where keratinocyte skin cancers make up at least 50% of included skin cancers” in order to keep the focus on keratinocyte skin cancers
for this review and in order not to replicate analyses conducted for the review of RCM for melanoma. These changes also affect the
definition of the secondary target condition in the Methods section. Heterogeneity investigations were limited by the data available.
Population inclusion criteria amended from inclusion of adults with lesions suspicious for keratinocyte skin cancer to inclusion of
adults with lesions suspicious for any skin cancer, on the basis that studies targeting those with pigmented skin lesions or with lesions
suspicious for melanoma also reported 2×2 contingency data for the detection of BCC or cSCC within these populations. We added a
requirement for a minimum of five benign lesions as well as five malignant lesions. The size threshold of five was arbitrary. However,
such small studies are unlikely to add precision to estimates of accuracy.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology); however, due to volume of evidence retrieved from database searches and time restrictions, we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic. In terms of analysis, restriction to
analysis of per participant data was not performed due to lack of data. Sensitivity analyses were not performed as planned due to lack
of data.
We intended to analyse studies separately according to in- person and image-based assessments; however, we were unable to do so due
to lack of data.
Studies using cross-validation, such as ’leave-one-out’ cross-validation were excluded rather than included as these methods are not
sufficiently robust and are likely to produce unrealistic estimates of test accuracy.
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To improve clarity of methods and to allow inclusion of studies presenting simple algorithms consisting of lesion characteristics that
had previously been suggested as associated with BCC or cSCC: this text from the protocol, “We will include studies developing new
algorithms or methods of diagnosis (i.e. derivation studies) if they use a separate independent ’test set’ of participants or images to
evaluate the new approach. We will also include studies using other forms of cross validation, such as ’leave-one-out’ cross-validation
(Efron 1983). We will note for future reference (but not extract) any data on the accuracy of lesion characteristics individually, e.g. the
presence or absence of a pigment network or detection of asymmetry,” has been replaced with “We included studies developing new
algorithms or methods of diagnosis (i.e. derivation studies) if they:
• used a separate independent ’test set’ of participants or images to evaluate the new approach, or
• investigated lesion characteristics that had previously been suggested as associated with BCC or cSCC and the study reported
accuracy based on the presence or absence of particular combinations of characteristics.
We excluded studies if they:
• used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no separate
test set;
• used cross-validation approaches such as ’leave-one-out’ cross-validation (Efron 1983);
• evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no overall
diagnosis of malignancy.”
Although we extracted any reporting of special interest or accreditation in skin cancer according to observer expertise, we were unable
to analyse the effect on accuracy due to lack of data.
As per the change to secondary objectives, this text from the protocol “For our secondary objective, the target condition will include
any skin lesion requiring excision. We will include studies reporting data for keratinocyte skin cancer combined, and not differentiated
according to BCC or cSCC, in this analysis, along with any melanoma or rare skin cancer (e.g. Merkel or amelanotic melanoma)
that may be detected. We will not consider in situ cancers or actinic keratosis as disease-positive” has been changed to “An additional
definition of the target condition was considered in secondary analysis, the detection of:
• any skin cancer, including BCC, cSCC, melanoma, or any rare skin cancer (e.g. Merkel cell cancer), as long as skin cancers other
than melanoma made up more than 50% of the disease positive group. Data from studies in which melanoma accounted for more
than 50% of skin cancers were included in the review of RCM for the diagnosis of melanoma (Dinnes 2018a).”
Added the following as possible sources of heterogeneity in Appendix 1:
• participant population: primary/secondary/specialist unit;
• lesion suspicion: general suspicion/atypical/equivocal/not reported;
• lesion type: any pigmented; melanocytic;
• inclusion of multiple lesions per participant.
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